Download PDF

Clinical Trial Results:
A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS

Summary
EudraCT number	2016-001103-23
Trial protocol	HU CZ DE GB
Global end of trial date	16 Jul 2018

Results information
Results version number	v2(current)
This version publication date	13 Dec 2020
First version publication date	08 Sep 2019
Other versions	v1
Version creation reason	Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review.

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

PA0008

ISRCTN number

US NCT number

NCT02969525

WHO universal trial number (UTN)

Sponsor organisation name

UCB Biopharma SPRL

Sponsor organisation address

Allée de la Recherche 60, Brussels, Belgium, 1070

Public contact

Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Scientific contact

Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

06 Dec 2018

Is this the analysis of the primary completion data?

Global end of trial reached?

Yes

Global end of trial date

16 Jul 2018

Was the trial ended prematurely?

Main objective of the trial

Assess the dose-response based on the efficacy of bimekizumab.

Protection of trial subjects

During this study all study participants were closely monitored.

Background therapy

Background therapy as permitted in the protocol. No medication increases or decreases were permitted for medications taken for psoriatic arthritis (PsA) until after the Week 16 protocol assessments. However, a decrease in dosing or dosing frequency of any agent was permitted for reasons of intolerance/Adverse Events (AEs)/side effects at any time.

Evidence for comparator

Not applicable

Actual start date of recruitment

27 Oct 2016

Long term follow-up planned

Yes

Long term follow-up rationale

Efficacy, Safety

Long term follow-up duration

2 Years

Independent data monitoring committee (IDMC) involvement?

Yes

Number of subjects enrolled per country

Country: Number of subjects enrolled

Czechia: 26

Country: Number of subjects enrolled

Germany: 16

Country: Number of subjects enrolled

Hungary: 3

Country: Number of subjects enrolled

Poland: 108

Country: Number of subjects enrolled

Russian Federation: 13

Country: Number of subjects enrolled

United States: 40

Worldwide total number of subjects

206

EEA total number of subjects

153

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

185

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

The study started to enroll patients in October 2016 and concluded in July 2018.

Screening details

The study included a 28-Day Screening Period, followed by a Double-blind Period from Day 1 to Week 12, prior to treatment re-randomization, a Dose-blind Period, from Week 12 after the treatment re-randomization and up to Week 48 and a Safety Follow-Up (SFU) Period, post week 48. The Participant Flow refers to the Randomized Set and Dose-Blind Set.

Period 1 title

Double-Blind Period

Is this the baseline period?

Yes

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Carer, Assessor

Are arms mutually exclusive

Yes

Placebo

Arm description

Participants received Placebo during the 12 Weeks Double-Blind Period.

Arm type

Placebo

Investigational medicinal product name

Placebo

Investigational medicinal product code

PBO

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered Placebo, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 16 mg

Arm description

Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 160 mg

Arm description

Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 160 mg LD

Arm description

Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 320 mg

Arm description

Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

Number of subjects in period 1	Placebo	BKZ 16 mg	BKZ 160 mg	BKZ 160 mg LD	BKZ 320 mg
Started	42	41	41	41	41
Completed Double-Blind Period	42	41	40	39	41
Completed Wk12 and started Dose-Blind	40	41	40	37	41
Completed	40	41	40	37	41
Not completed	2	0	1	4	0
Study medication discontinued prior Wk12	2	-	-	2	-
Adverse event, non-fatal	-	-	1	1	-
LOW EGFR	-	-	-	1	-

Period 2 title

Dose-Blind Period

Is this the baseline period?

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Carer, Assessor

Are arms mutually exclusive

Yes

Placebo - BKZ 160 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

Placebo - BZK 320 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 16 mg - BKZ 160 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BZK 16 mg - BZK 320 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BZK 160 mg LD - BZK 160 mg

Arm description

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BZK 160 mg - BKZ dose 160 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

BKZ 320 mg - BKZ 320 mg

Arm description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.

Arm type

Experimental

Investigational medicinal product name

Bimekizumab

Investigational medicinal product code

UCB4940

Other name

Pharmaceutical forms

Solution for injection

Routes of administration

Subcutaneous use

Dosage and administration details

Subjects were administered different BKZ doses, as 2 subcutaneous injections, in the lateral abdominal wall, or upper outer thigh.

Number of subjects in period 2	Placebo - BKZ 160 mg	Placebo - BZK 320 mg	BKZ 16 mg - BKZ 160 mg	BZK 16 mg - BZK 320 mg	BZK 160 mg LD - BZK 160 mg	BZK 160 mg - BKZ dose 160 mg	BKZ 320 mg - BKZ 320 mg
Started	20	20	22	19	37	40	41
Completed	20	18	22	18	34	38	39
Not completed	0	2	0	1	3	2	2
Consent withdrawn by subject	-	2	-	1	2	-	-
Non-cooperating patient	-	-	-	-	-	-	1
Adverse event, non-fatal	-	-	-	-	1	1	1
Withdrew before Safety Follow-up visit	-	-	-	-	-	1	-

Baseline characteristics

Top of page

Reporting group title

Placebo

Reporting group description

Participants received Placebo during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 16 mg

Reporting group description

Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 160 mg

Reporting group description

Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Reporting group title

BKZ 160 mg LD

Reporting group description

Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 320 mg

Reporting group description

Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Reporting group values	Placebo	BKZ 16 mg	BKZ 160 mg	BKZ 160 mg LD	BKZ 320 mg	Total
Number of subjects	42	41	41	41	41	206
Age categorical
Units: Subjects
<=18 years	0	0	0	0	0	0
Between 18 and 65 years	38	35	40	36	36	185
>=65 years	4	6	1	5	5	21
Age continuous
Units: years
arithmetic mean (standard deviation)	49.02 ( 12.07 )	49.98 ( 13.56 )	48.00 ( 11.65 )	49.05 ( 12.99 )	50.39 ( 12.08 )	-
Gender categorical
Units: Subjects
Male	24	24	20	14	23	105
Female	18	17	21	27	18	101

End points

Top of page

Reporting group title

Placebo

Reporting group description

Participants received Placebo during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 16 mg

Reporting group description

Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 160 mg

Reporting group description

Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Reporting group title

BKZ 160 mg LD

Reporting group description

Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.

Reporting group title

BKZ 320 mg

Reporting group description

Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.

Reporting group title

Placebo - BKZ 160 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.

Reporting group title

Placebo - BZK 320 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.

Reporting group title

BKZ 16 mg - BKZ 160 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.

Reporting group title

BZK 16 mg - BZK 320 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.

Reporting group title

BZK 160 mg LD - BZK 160 mg

Reporting group description

Reporting group title

BZK 160 mg - BKZ dose 160 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.

Reporting group title

BKZ 320 mg - BKZ 320 mg

Reporting group description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.

Subject analysis set title

Placebo (FAS)

Subject analysis set type

Full analysis

Subject analysis set description

Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).

Subject analysis set title

BKZ 16 mg (FAS)

Subject analysis set type

Full analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).

Subject analysis set title

BKZ 160 mg (FAS)

Subject analysis set type

Full analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).

Subject analysis set title

BKZ 160 mg LD (FAS)

Subject analysis set type

Full analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).

Subject analysis set title

BKZ 320 mg (FAS)

Subject analysis set type

Full analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).

Subject analysis set title

Placebo - BKZ 160 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

Placebo - BZK 320 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

BKZ 16 mg - BKZ 160 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

BZK 16 mg - BZK 320 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

BZK 160 mg LD - BZK 160 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

BZK 160 mg - BKZ 160 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

BKZ 320 mg - BKZ 320 mg (DBS)

Subject analysis set type

Per protocol

Subject analysis set description

After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period. Participants are a subgroup from the Dose-Blind Set (DBS). The subgroup contained participants who were part of the PK-PPS and DBS.

Subject analysis set title

Placebo (SS)

Subject analysis set type

Safety analysis

Subject analysis set description

Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Safety Set (SS).

Subject analysis set title

BKZ 16 mg (SS)

Subject analysis set type

Safety analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.

Subject analysis set title

BKZ 160 mg (SS)

Subject analysis set type

Safety analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.

Subject analysis set title

BKZ 160 mg LD (SS)

Subject analysis set type

Safety analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the SS.

Subject analysis set title

BKZ 320 mg (SS)

Subject analysis set type

Safety analysis

Subject analysis set description

Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the SS.

Subject analysis set title

Placebo (SS) - up to Wk 12

Subject analysis set type

Safety analysis

Subject analysis set description

This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).

Subject analysis set title

BKZ 16 mg (SS) - up to Wk 12

Subject analysis set type

Safety analysis

Subject analysis set description

This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.

Subject analysis set title

BKZ 160 mg & 160 mg LD (SS) - up to Wk 68

Subject analysis set type

Safety analysis

Subject analysis set description

This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.

Subject analysis set title

BKZ 320 mg (SS) - up to Wk 68

Subject analysis set type

Safety analysis

Subject analysis set description

This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.

Primary: ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12

Top of page

End point title

ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12

End point description

The ACR50 response rate was based on 50% improvement relative to Baseline in the following measures: •Tender Joint Count (TJC) based on 78 joints •Swollen Joint Count (SJC) based on 76 joints •3 of the 5 remaining core set measures: -Disease activity as assessed by Patient’s Global Assessment of Disease Activity (PGADA) -Disease activity as assessed by Physician’s Global Assessment of Disease Activity (PhGADA) -Pain as assessed by Patient’s Assessment of Arthritis Pain (PtAAP) -Physical function as assessed by Health Assessment Questionnaire – Disability Index (HAQ-DI) -Acute phase response as assessed by high sensitivity C-reactive protein (hs CRP). The Full Analysis Set (FAS) consisted of all randomized study participants who received at least 1 dose of investigational medicinal product (IMP) and had a valid measurement of the primary efficacy variable at Baseline.

End point type

Primary

End point timeframe

Week 12

End point values	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Number of subjects analysed	42	41	41	41	41
Units: percentage of subjects
number (not applicable)	7.1	26.8	41.5	46.3	24.4

Statistical analysis 1

Statistical analysis description

Statistic and p-value were calculated using a Cochran-Mantel-Haenszel test (test for non-zero correlation statistic) based on modified ridit scores and including geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure as stratification factors. The 160 loading dose arm was not considered in the dose-response because this is a mixed dose and the test is examining linear dose response.

Comparison groups

Placebo (FAS) v BKZ 16 mg (FAS) v BKZ 160 mg (FAS) v BKZ 160 mg LD (FAS) v BKZ 320 mg (FAS)

Number of subjects included in analysis

206

Analysis specification

Pre-specified

Analysis type

other ^[1]

P-value

= 0.031

Method

Cochran-Mantel-Haenszel

Parameter type

Correlation statistic

Point estimate

999

Confidence interval

level

sides

2-sided

lower limit

999

upper limit

999

Notes
[1] - 999 and 0% CI are used as placeholders. Using this methodology no point estimator was calculated. The respective correlation statistic was 4.6.

Statistical analysis 2

Statistical analysis description

For differences in relation to placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Factor Necrosis (TNF) inhibitor exposure.

Comparison groups

Placebo (FAS) v BKZ 16 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other ^[2]

P-value

= 0.032 ^[3]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

4.2

Confidence interval

level

95%

sides

2-sided

lower limit

1.13

upper limit

15.23

Notes
[2] - The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
[3] - The p-values were displayed as nominal p-values.

Statistical analysis 3

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other ^[4]

P-value

= 0.001 ^[5]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

8.1

Confidence interval

level

95%

sides

2-sided

lower limit

2.28

upper limit

28.74

Notes
[4] - The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
[5] - The p-values were displayed as nominal p-values.

Statistical analysis 4

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg LD (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other ^[6]

P-value

< 0.001 ^[7]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

9.7

Confidence interval

level

95%

sides

2-sided

lower limit

2.73

upper limit

34.26

Notes
[6] - The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
[7] - The p-values were displayed as nominal p-values.

Statistical analysis 5

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 320 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other ^[8]

P-value

= 0.051 ^[9]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

3.7

Confidence interval

level

95%

sides

2-sided

lower limit

upper limit

13.68

Notes
[8] - The pairwise testing of each bimekizumab dose versus placebo accounted for multiplicity by using a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. If the sequential testing failed to reach significance at a significance level of alpha=0.05, then the pairwise testing continued and the comparison was seen as non-significant.
[9] - The p-values were displayed as nominal p-values.

Secondary: ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12

Top of page

End point title

ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12

End point description

The ACR20 response rate was based on 20% improvement relative to Baseline in the following measures: •TJC based on 78 joints •SJC based on 76 joints •3 of the 5 remaining core set measures: -Disease activity as assessed by PGADA -Disease activity as assessed by PhGADA -Pain as assessed by PtAAP -Physical function as assessed by HAQ-DI -Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis. The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

End point type

Secondary

End point timeframe

Week 12

End point values	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Number of subjects analysed	42	41	41	41	41
Units: percentage of subjects
number (not applicable)	19.0	53.7	73.2	61.0	51.2

Statistical analysis 1

Statistical analysis description

For differences in relation to Placebo: Odds Ratio, confidence interval, and p-value were derived from a logistic regression model including fixed effects for treatment, geographic region and prior Tumor Necrosis Factor (TNF) inhibitor exposure.

Comparison groups

Placebo (FAS) v BKZ 16 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.002 ^[10]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

4.6

Confidence interval

level

95%

sides

2-sided

lower limit

1.73

upper limit

12.39

Notes
[10] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 2

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

< 0.001 ^[11]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

Confidence interval

level

95%

sides

2-sided

lower limit

3.91

upper limit

30.95

Notes
[11] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 3

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg LD (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

< 0.001 ^[12]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

6.2

Confidence interval

level

95%

sides

2-sided

lower limit

2.31

upper limit

16.84

Notes
[12] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 4

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 320 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.004 ^[13]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

4.2

Confidence interval

level

95%

sides

2-sided

lower limit

1.59

upper limit

11.35

Notes
[13] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Secondary: ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12

Top of page

End point title

ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12

End point description

The ACR70 response rate was based on 70% improvement relative to Baseline in the following measures: •TJC based on 78 joints •SJC based on 76 joints •3 of the 5 remaining core set measures: -Disease activity as assessed by PGADA -Disease activity as assessed by PhGADA -Pain as assessed by PtAAP -Physical function as assessed by HAQ-DI -Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis. The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

End point type

Secondary

End point timeframe

Week 12

End point values	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Number of subjects analysed	42	41	41	41	41
Units: percentage of subjects
number (not applicable)	4.8	12.2	19.5	31.7	14.6

Statistical analysis 1

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 16 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.279 ^[14]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

2.4

Confidence interval

level

95%

sides

2-sided

lower limit

0.5

upper limit

11.31

Notes
[14] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 2

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.065 ^[15]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

4.1

Confidence interval

level

95%

sides

2-sided

lower limit

0.92

upper limit

17.88

Notes
[15] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 3

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 160 mg LD (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.006 ^[16]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

7.5

Confidence interval

level

95%

sides

2-sided

lower limit

1.77

upper limit

31.28

Notes
[16] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Statistical analysis 4

Statistical analysis description

Comparison groups

Placebo (FAS) v BKZ 320 mg (FAS)

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

other

P-value

= 0.172 ^[17]

Method

Regression, Logistic

Parameter type

Odds ratio (OR)

Point estimate

2.9

Confidence interval

level

95%

sides

2-sided

lower limit

0.63

upper limit

13.39

Notes
[17] - No sequential testing procedure was used for the secondary efficacy variables. The p-values were displayed as nominal p-values.

Secondary: PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Top of page

End point title

PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

End point description

PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness/thickness/scaliness of the psoriatic lesions (0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness/thickness/scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person’s affected skin for the respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Subset of study participants in the FAS with ≥3% PSO BSA at Baseline (NRI).

End point type

Secondary

End point timeframe

Week 12

End point values	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Number of subjects analysed	20	14	16	17	11
Units: percentage of subjects
number (not applicable)	10.0	35.7	62.5	52.9	45.5

No statistical analyses for this end point

Secondary: PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Top of page

End point title

PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

End point description

PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness/thickness/scaliness of the psoriatic lesions (0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness/thickness/scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person’s affected skin for the respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Subset of study participants in the FAS with ≥3% PSO BSA at Baseline (NRI).

End point type

Secondary

End point timeframe

Week 12

End point values	Placebo (FAS)	BKZ 16 mg (FAS)	BKZ 160 mg (FAS)	BKZ 160 mg LD (FAS)	BKZ 320 mg (FAS)
Number of subjects analysed	20	14	16	17	11
Units: percentage of subjects
number (not applicable)	10.0	57.1	68.8	70.6	72.7

No statistical analyses for this end point

Secondary: Percentage of participants with at least one adverse event (AE) during the study

Top of page

End point title

Percentage of participants with at least one adverse event (AE) during the study

End point description

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

End point type

Secondary

End point timeframe

From Screening Period until the Safety Follow-Up Visit (up to Week 72)

End point values	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Number of subjects analysed	42	39	126	80
Units: percentage of participants
number (not applicable)	57.1	33.33	74.6	72.5

No statistical analyses for this end point

Secondary: Percentage of participants with at least one serious adverse event (SAE) during the study

Top of page

End point title

Percentage of participants with at least one serious adverse event (SAE) during the study

End point description

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: • Results in death • Is life-threatening • Requires in patient hospitalization or prolongation of existing hospitalization • Is a congenital anomaly or birth defect • Is an infection that requires treatment parenteral antibiotics • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

End point type

Secondary

End point timeframe

From Screening Period until the Safety Follow-Up Visit (up to Week 72)

End point values	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Number of subjects analysed	42	39	126	80
Units: percentage of participants
number (not applicable)	2.4	0	6.3	0

No statistical analyses for this end point

Secondary: Percentage of participants who withdrew due to an adverse event (AE) during the study

Top of page

End point title

Percentage of participants who withdrew due to an adverse event (AE) during the study

End point description

End point type

Secondary

End point timeframe

From Screening Period until the Safety Follow-Up Visit (up to Week 72)

End point values	Placebo (SS) - up to Wk 12	BKZ 16 mg (SS) - up to Wk 12	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 320 mg (SS) - up to Wk 68
Number of subjects analysed	42	39	126	80
Units: percentage of participants
number (not applicable)	4.8	0	4.8	2.5

No statistical analyses for this end point

Secondary: Changes from Baseline in vital signs during the study (diastolic blood pressure, systolic blood pressure)

Top of page

End point title

Changes from Baseline in vital signs during the study (diastolic blood pressure, systolic blood pressure)

End point description

Diastolic and systolic blood pressure (BP) were measured in millimeters of mercury (mmHg). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	42	39	43	41	41
Units: mmHg
arithmetic mean (standard deviation)
Diastolic BP 30 min post dose (42, 39, 43, 41, 41)	1.3 ( 8.9 )	-1.2 ( 4.9 )	-1.2 ( 5.4 )	0.6 ( 6.1 )	-0.6 ( 5.3 )
Diastolic BP 1 h post dose (42, 39, 43, 41, 41)	1.1 ( 8.8 )	-2.0 ( 6.3 )	-0.7 ( 8.1 )	1.2 ( 6.7 )	-1.0 ( 5.5 )
Diastolic BP Wk 1 (41, 39, 43, 41, 41)	0.1 ( 9.6 )	-0.3 ( 6.5 )	0.6 ( 11.4 )	-0.9 ( 6.6 )	-0.4 ( 6.5 )
Diastolic BP Wk 2 (42, 39, 43, 41, 41)	0.7 ( 10.4 )	-0.7 ( 6.5 )	-1.0 ( 8.9 )	-2.7 ( 8.3 )	-0.1 ( 9.0 )
Diastolic BP Wk 4 pre-dose (41, 39, 42, 41, 41)	0.0 ( 8.2 )	-1.7 ( 8.4 )	-1.4 ( 10.7 )	-0.8 ( 7.8 )	-1.3 ( 7.4 )
Diastolic BP Wk 4 post dose (41, 39, 41, 40, 40)	-2.0 ( 8.7 )	-1.0 ( 7.3 )	-1.2 ( 8.9 )	-0.9 ( 8.3 )	-1.6 ( 7.6 )
Diastolic BP Wk 8 pre-dose (41, 39, 43, 39, 41)	1.0 ( 8.2 )	-1.3 ( 8.7 )	0.3 ( 8.7 )	-0.5 ( 7.0 )	0.2 ( 6.9 )
Diastolic BP Wk 8 post dose (41, 39, 42, 39, 41)	-0.9 ( 9.1 )	-1.1 ( 8.4 )	0.6 ( 8.7 )	-0.7 ( 7.3 )	-2.2 ( 7.4 )
Diastolic BP Wk 12 pre-dose (42, 39, 42, 39, 41)	0.2 ( 9.1 )	-1.1 ( 10.4 )	0.2 ( 8.5 )	-1.5 ( 7.9 )	-0.6 ( 8.2 )
Diastolic BP Wk 12 post dose (40, 39, 42, 37, 41)	-0.3 ( 9.6 )	-2.0 ( 10.0 )	0.3 ( 8.3 )	-1.8 ( 7.9 )	-2.6 ( 8.0 )
Diastolic BP Wk 16 pre-dose (42, 39, 42, 38, 41)	-2.7 ( 9.6 )	-3.5 ( 8.9 )	-0.8 ( 8.6 )	-1.2 ( 8.7 )	-0.4 ( 7.9 )
Diastolic BP Wk 16 post dose (40, 39, 39, 36, 39)	-3.0 ( 9.1 )	-1.9 ( 8.3 )	-1.7 ( 9.2 )	-1.1 ( 7.9 )	-2.4 ( 8.7 )
Diastolic BP Wk 20 pre-dose (40, 39, 42, 37, 40)	0.5 ( 10.3 )	-1.8 ( 9.0 )	-0.6 ( 8.3 )	-1.4 ( 8.3 )	-1.8 ( 7.3 )
Diastolic BP Wk 20 post dose (39, 39, 38, 36, 40)	0.1 ( 9.5 )	-3.1 ( 8.3 )	-0.4 ( 9.2 )	-3.0 ( 9.3 )	-2.6 ( 7.1 )
Diastolic BP Wk 24 pre-dose (39, 39, 41, 36, 40)	-0.4 ( 7.6 )	-1.6 ( 7.2 )	-0.7 ( 9.3 )	1.0 ( 6.9 )	-1.0 ( 6.6 )
Diastolic BP Wk 24 post dose (39, 38, 38, 35, 39)	-0.6 ( 7.5 )	-1.7 ( 7.9 )	-0.3 ( 8.2 )	-0.3 ( 7.6 )	-1.4 ( 7.9 )
Diastolic BP Wk 28 pre-dose (39, 39, 41, 35, 40)	1.4 ( 7.9 )	-0.6 ( 9.7 )	0.9 ( 9.5 )	-0.6 ( 6.9 )	-0.5 ( 7.5 )
Diastolic BP Wk 28 post dose (38, 39, 39, 34, 39)	1.2 ( 8.7 )	-2.0 ( 9.4 )	1.2 ( 9.0 )	-0.2 ( 7.1 )	-1.8 ( 7.1 )
Diastolic BP Wk 32 pre-dose (39, 39, 40, 35, 39)	0.2 ( 8.5 )	-1.7 ( 8.6 )	1.6 ( 9.2 )	-0.3 ( 9.3 )	-1.2 ( 8.6 )
Diastolic BP Wk 32 post dose (36, 39, 37, 34, 39)	0.7 ( 10.0 )	-3.0 ( 8.6 )	0.1 ( 9.6 )	-0.6 ( 8.5 )	-2.1 ( 8.5 )
Diastolic BP Wk 36 pre-dose (38, 38, 41, 34, 39)	0.0 ( 8.6 )	-0.6 ( 9.2 )	1.4 ( 8.9 )	-0.9 ( 7.2 )	0.8 ( 7.5 )
Diastolic BP Wk 36 post dose (37, 38, 38, 31, 38)	1.6 ( 7.7 )	-1.6 ( 9.2 )	1.3 ( 9.3 )	-1.7 ( 6.8 )	-0.1 ( 7.1 )
Diastolic BP Wk 40 pre-dose (37, 38, 41, 34, 40)	0.8 ( 7.6 )	-2.5 ( 9.7 )	1.0 ( 9.5 )	-1.0 ( 7.2 )	-1.9 ( 6.8 )
Diastolic BP Wk 40 post dose (37, 38, 40, 33, 37)	0.9 ( 7.7 )	-1.8 ( 9.1 )	0.2 ( 8.3 )	-0.8 ( 6.6 )	-0.1 ( 7.3 )
Diastolic BP Wk 44 pre-dose (38, 38, 41, 34, 40)	1.4 ( 9.3 )	-2.1 ( 7.7 )	1.3 ( 9.2 )	-0.4 ( 6.7 )	-2.4 ( 10.9 )
Diastolic BP Wk 44 post dose (36, 38, 40, 33, 39)	2.3 ( 9.2 )	-1.3 ( 7.6 )	-0.7 ( 8.7 )	-1.4 ( 8.1 )	-1.5 ( 6.5 )
Diastolic BP Wk 48 (38, 38, 41, 34, 40)	1.8 ( 9.2 )	0.4 ( 9.7 )	1.1 ( 9.1 )	0.6 ( 8.7 )	-0.8 ( 6.4 )
Systolic BP 30 min post dose (42, 39, 43, 41, 41)	0.8 ( 8.1 )	0.5 ( 9.7 )	-0.8 ( 8.2 )	1.5 ( 8.8 )	-2.5 ( 9.7 )
Systolic BP 1 hour post dose (42, 39, 43, 41, 41)	-0.6 ( 9.4 )	-2.0 ( 10.5 )	0.2 ( 8.7 )	1.0 ( 8.4 )	-1.8 ( 7.1 )
Systolic BP Wk 1 (41, 39, 43, 41, 41)	-1.7 ( 10.8 )	-1.3 ( 10.0 )	1.7 ( 12.9 )	-2.4 ( 8.3 )	-1.6 ( 11.0 )
Systolic BP Wk 2 (42, 39, 43, 41, 41)	-0.7 ( 12.9 )	-0.2 ( 9.8 )	-0.1 ( 13.2 )	-2.7 ( 8.2 )	-0.4 ( 11.9 )
Systolic BP Wk 4 pre-dose (41, 39, 42, 41, 41)	-2.6 ( 11.4 )	-1.5 ( 10.6 )	-1.0 ( 13.0 )	-2.3 ( 10.5 )	-2.7 ( 11.2 )
Systolic BP Wk 4 post dose (41, 39, 41, 40, 40)	-3.5 ( 12.1 )	-0.6 ( 10.4 )	-2.2 ( 11.8 )	-0.6 ( 9.1 )	-3.7 ( 11.3 )
Systolic BP Wk 8 pre-dose (41, 39, 43, 39, 41)	-2.1 ( 13.1 )	-0.8 ( 10.7 )	-1.1 ( 11.3 )	-3.6 ( 11.7 )	-1.3 ( 10.4 )
Systolic BP Wk 8 post dose (41, 39, 42, 39, 41)	-3.2 ( 12.6 )	-1.9 ( 11.6 )	-0.3 ( 11.1 )	-2.8 ( 10.2 )	-1.9 ( 12.0 )
Systolic BP Wk 12 pre-dose (42, 39, 42, 39, 41)	-3.3 ( 12.4 )	1.6 ( 13.7 )	-3.1 ( 11.7 )	-4.4 ( 10.8 )	-2.6 ( 9.7 )
Systolic BP Wk 12 post dose (40, 39, 42, 37, 41)	-3.9 ( 14.1 )	2.1 ( 11.1 )	-1.9 ( 12.0 )	-3.6 ( 10.1 )	-2.4 ( 10.1 )
Systolic BP Wk 16 pre-dose (42, 39, 42, 38, 41)	-3.6 ( 15.1 )	-2.3 ( 12.3 )	-4.3 ( 11.3 )	-4.3 ( 12.5 )	-2.3 ( 11.4 )
Systolic BP Wk 16 post dose (40, 39, 39, 36, 39)	-3.7 ( 17.1 )	-2.6 ( 11.7 )	-3.4 ( 12.7 )	-2.7 ( 11.0 )	-5.7 ( 8.5 )
Systolic BP Wk 20 pre-dose (40, 39, 42, 37, 40)	-2.0 ( 13.1 )	-3.2 ( 12.5 )	-2.6 ( 11.9 )	-5.4 ( 9.7 )	-4.5 ( 10.5 )
Systolic BP Wk 20 post dose (39, 39, 38, 36, 40)	-1.9 ( 14.5 )	-3.2 ( 13.0 )	-3.7 ( 12.2 )	-7.9 ( 11.9 )	-4.4 ( 9.9 )
Systolic BP Wk 24 pre-dose (39, 39, 41, 36, 40)	-3.1 ( 10.5 )	-1.1 ( 9.5 )	-2.7 ( 12.3 )	-3.6 ( 10.1 )	-0.3 ( 10.5 )
Systolic BP Wk 24 post dose (39, 38, 38, 35, 39)	-2.6 ( 10.9 )	-2.8 ( 10.5 )	-2.2 ( 11.7 )	-3.0 ( 9.7 )	-1.1 ( 10.5 )
Systolic BP Wk 28 pre-dose (39, 39, 41, 35, 40)	-0.1 ( 11.4 )	-2.5 ( 12.8 )	-2.5 ( 13.1 )	0.4 ( 11.6 )	-2.9 ( 11.3 )
Systolic BP Wk 28 post dose (38, 39, 39, 34, 39)	-1.1 ( 12.1 )	-2.9 ( 11.1 )	-2.6 ( 12.4 )	-0.7 ( 11.9 )	-4.6 ( 11.2 )
Systolic BP Wk 32 pre-dose (39, 39, 40, 35, 39)	-0.9 ( 13.1 )	-1.5 ( 13.3 )	-0.6 ( 12.4 )	0.6 ( 11.0 )	-3.7 ( 12.4 )
Systolic BP Wk 32 post dose (36, 39, 37, 34, 39)	-1.7 ( 12.6 )	-2.2 ( 11.6 )	0.3 ( 12.5 )	-0.4 ( 11.1 )	-4.8 ( 10.6 )
Systolic BP Wk 36 pre-dose (38, 38, 41, 34, 39)	-3.1 ( 11.9 )	1.1 ( 13.9 )	-0.2 ( 13.6 )	-1.8 ( 11.2 )	-3.2 ( 11.1 )
Systolic BP Wk 36 post dose (37, 38, 38, 31, 38)	-0.6 ( 11.1 )	1.3 ( 12.6 )	-0.5 ( 12.4 )	-3.8 ( 10.8 )	-3.8 ( 11.4 )
Systolic BP Wk 40 pre-dose (37, 38, 41, 34, 40)	-3.3 ( 12.1 )	-3.1 ( 11.4 )	-1.6 ( 12.9 )	-4.0 ( 9.5 )	-1.2 ( 11.0 )
Systolic BP Wk 40 post dose (37, 38, 40, 33, 37)	-2.3 ( 11.7 )	-0.4 ( 12.7 )	-1.2 ( 13.8 )	-3.2 ( 11.6 )	-2.2 ( 9.6 )
Systolic BP Wk 44 pre-dose (38, 38, 41, 34, 40)	-2.8 ( 12.3 )	-2.8 ( 9.9 )	0.0 ( 13.1 )	-5.1 ( 9.9 )	-3.9 ( 10.3 )
Systolic BP Wk 44 post dose (36, 38, 40, 33, 39)	-1.8 ( 14.5 )	-1.2 ( 9.5 )	-0.6 ( 10.4 )	-4.6 ( 10.3 )	-3.8 ( 10.5 )
Systolic BP Wk 48 (38, 38, 41, 34, 40)	-1.1 ( 14.0 )	-0.1 ( 12.5 )	-0.1 ( 12.6 )	-2.8 ( 11.5 )	-5.2 ( 9.6 )

No statistical analyses for this end point

Secondary: Changes from Baseline in vital signs during the study (pulse rate)

Top of page

End point title

Changes from Baseline in vital signs during the study (pulse rate)

End point description

Pulse rate was measured in beats per minute (beats/min). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	42	39	43	41	41
Units: beats/min
arithmetic mean (standard deviation)
30 min post dose (42, 39, 43, 41, 41)	0.4 ( 5.4 )	-0.8 ( 5.6 )	-1.5 ( 7.2 )	-2.3 ( 7.5 )	-1.1 ( 7.2 )
1 hour post dose (42, 39, 43, 41, 41)	0.3 ( 6.7 )	1.0 ( 11.3 )	-0.8 ( 7.6 )	-0.8 ( 8.1 )	-0.4 ( 7.0 )
Week 1 (41, 39, 43, 41, 41)	2.9 ( 8.3 )	-1.5 ( 7.5 )	-0.7 ( 7.1 )	0.6 ( 8.9 )	-0.8 ( 9.0 )
Week 2 (42, 39, 43, 41, 41)	1.2 ( 6.4 )	-1.7 ( 5.7 )	-0.7 ( 7.9 )	-1.0 ( 9.1 )	-0.4 ( 6.9 )
Week 4 pre-dose (41, 39, 42, 41, 41)	-0.2 ( 5.3 )	-2.1 ( 6.9 )	-1.9 ( 8.1 )	0.1 ( 9.8 )	-1.0 ( 6.6 )
Week 4 post dose (41, 39, 41, 40, 40)	0.4 ( 8.6 )	-2.6 ( 6.6 )	-2.7 ( 9.5 )	-0.5 ( 9.4 )	-1.1 ( 6.2 )
Week 8 pre-dose (41, 39, 43, 39, 41)	0.9 ( 6.5 )	-0.6 ( 8.0 )	-1.6 ( 8.6 )	0.8 ( 6.9 )	-1.3 ( 8.2 )
Week 8 post dose (41, 39, 42, 39, 41)	-0.1 ( 6.9 )	-1.3 ( 8.6 )	-1.9 ( 8.6 )	0.0 ( 8.5 )	-2.3 ( 8.3 )
Week 12 pre-dose (42, 39, 42, 39, 41)	1.1 ( 10.2 )	-2.2 ( 8.5 )	-2.9 ( 10.5 )	-1.7 ( 9.5 )	-1.1 ( 8.4 )
Week 12 post dose (40, 39, 42, 37, 41)	-0.6 ( 8.8 )	-3.3 ( 8.8 )	-3.6 ( 9.4 )	-2.1 ( 9.7 )	-2.0 ( 7.8 )
Week 16 pre-dose (42, 39, 42, 38, 41)	-0.2 ( 8.5 )	-2.1 ( 5.8 )	-2.9 ( 8.0 )	-1.9 ( 10.1 )	-1.3 ( 7.2 )
Week 16 post dose (40, 39, 39, 36, 39)	-0.1 ( 9.9 )	-3.5 ( 5.5 )	-3.7 ( 9.7 )	-2.1 ( 9.8 )	-2.2 ( 7.3 )
Week 20 pre-dose (40, 39, 42, 37, 40)	-0.1 ( 10.3 )	-2.4 ( 7.0 )	-1.7 ( 10.3 )	0.0 ( 9.0 )	-1.2 ( 9.0 )
Week 20 post dose (39, 39, 38, 36, 40)	-0.7 ( 6.8 )	-2.3 ( 7.8 )	-2.1 ( 9.7 )	-0.1 ( 8.5 )	-1.3 ( 8.9 )
Week 24 pre-dose (39, 39, 41, 36, 40)	-0.5 ( 7.9 )	-2.0 ( 8.1 )	-2.8 ( 10.4 )	-0.7 ( 7.3 )	-1.2 ( 7.8 )
Week 24 post dose (39, 38, 38, 35, 39)	-0.9 ( 7.8 )	-2.9 ( 8.5 )	-3.0 ( 9.6 )	-1.3 ( 6.9 )	-2.5 ( 7.1 )
Week 28 pre-dose (39, 39, 41, 35, 40)	1.9 ( 9.7 )	-2.1 ( 10.0 )	0.0 ( 9.3 )	-0.5 ( 11.2 )	0.2 ( 8.3 )
Week 28 post dose (38, 39, 39, 34, 39)	1.8 ( 7.5 )	-3.0 ( 9.4 )	-0.5 ( 8.5 )	-0.8 ( 10.0 )	0.0 ( 7.5 )
Week 32 pre-dose (39, 39, 40, 35, 39)	3.3 ( 10.0 )	-0.9 ( 7.9 )	-2.0 ( 9.2 )	-1.2 ( 10.6 )	-0.3 ( 7.8 )
Week 32 post dose (36, 39, 37, 34, 39)	3.3 ( 8.4 )	-0.8 ( 7.8 )	-3.0 ( 9.5 )	-1.9 ( 9.6 )	-2.0 ( 8.8 )
Week 36 pre-dose (38, 38, 41, 34, 39)	0.7 ( 8.5 )	0.2 ( 7.5 )	-2.6 ( 8.6 )	-2.6 ( 10.2 )	-0.5 ( 9.7 )
Week 36 post dose (37, 38, 38, 31, 38)	1.1 ( 7.6 )	-0.8 ( 8.2 )	-3.0 ( 9.8 )	-2.5 ( 8.2 )	-1.4 ( 9.6 )
Week 40 pre-dose (37, 38, 41, 34, 40)	2.7 ( 10.3 )	-0.5 ( 8.8 )	1.0 ( 10.1 )	-1.7 ( 7.6 )	2.0 ( 9.4 )
Week 40 post dose (37, 38, 40, 33, 37)	0.9 ( 8.3 )	-1.7 ( 8.3 )	0.0 ( 8.9 )	-2.0 ( 8.4 )	0.5 ( 9.1 )
Week 44 pre-dose (38, 38, 41, 34, 40)	2.2 ( 8.9 )	-1.6 ( 6.9 )	-0.4 ( 10.1 )	-1.4 ( 8.2 )	0.7 ( 9.7 )
Week 44 post dose (36, 38, 40, 33, 38)	2.9 ( 6.9 )	-1.7 ( 8.0 )	-0.5 ( 11.0 )	-2.8 ( 7.7 )	-0.2 ( 10.3 )
Week 48 (38, 38, 41, 34, 40)	2.0 ( 8.9 )	-3.7 ( 7.8 )	-2.5 ( 10.4 )	-4.2 ( 9.5 )	-3.1 ( 9.5 )

No statistical analyses for this end point

Secondary: Changes from Baseline in body weight during the study

Top of page

End point title

Changes from Baseline in body weight during the study

End point description

Body weight was measured in kilograms. The SS consisted of all randomized study participants who received at least 1 dose of IMP. Overall number of participants analyzed include only those for whom body weight was measured and analyzed during the study. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 12, Week 24, Week 36 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	39	43	38	41
Units: kilograms
arithmetic mean (standard deviation)
Week 12 (41, 39, 43, 38, 41)	0.14 ( 3.38 )	-0.87 ( 3.12 )	0.21 ( 1.78 )	-0.38 ( 1.80 )	-0.04 ( 2.39 )
Week 24 (39, 38, 41, 36, 40)	0.33 ( 4.10 )	-0.03 ( 3.48 )	-0.07 ( 2.63 )	-0.13 ( 2.37 )	-0.39 ( 3.73 )
Week 36 (38, 38, 41, 34, 39)	0.32 ( 5.15 )	-0.14 ( 2.90 )	0.27 ( 3.42 )	0.15 ( 2.36 )	-0.04 ( 4.19 )
Week 48 (38, 38, 41, 34, 40)	0.21 ( 4.42 )	0.45 ( 3.41 )	0.80 ( 3.84 )	-0.14 ( 3.32 )	0.11 ( 4.24 )

No statistical analyses for this end point

Secondary: Changes from Baseline in electrocardiogram (ECG) intervals during the study (QTcB, QTcF, PR, QRS, QT, RR)

Top of page

End point title

Changes from Baseline in electrocardiogram (ECG) intervals during the study (QTcB, QTcF, PR, QRS, QT, RR)

End point description

Electrocardiogram (ECG) intervals (QTcB= QT interval corrected for heart rate (Bazett’s formula); QTcF= QT interval corrected for heart rate (Fridericia’s formula)) were measured in milliseconds. The SS consisted of all randomized study participants who received at least 1 dose of IMP. Overall number of participants analyzed include only those for whom electrocardiogram data was measured and analyzed during the study. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 12 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	38	36	42	34	40
Units: msec
arithmetic mean (standard deviation)
QTcB Week 12 (38, 36, 42, 34, 40)	3.4 ( 32.7 )	-2.8 ( 29.9 )	-5.6 ( 41.8 )	1.5 ( 18.2 )	-1.9 ( 31.4 )
QTcB Week 48 (35, 37, 40, 31, 39)	-2.5 ( 34.8 )	-5.8 ( 36.5 )	-5.9 ( 22.2 )	-4.7 ( 21.0 )	-5.7 ( 27.7 )
QTcF Week 12 (37, 32, 35, 32, 39)	4.5 ( 27.5 )	-2.5 ( 22.4 )	-2.2 ( 14.2 )	-0.5 ( 17.0 )	-3.0 ( 18.8 )
QTcF Week 48 (35, 32, 34, 29, 38)	-0.1 ( 30.7 )	-6.1 ( 31.4 )	-0.2 ( 15.6 )	-2.2 ( 20.0 )	4.6 ( 44.6 )
PR Week 12 (39, 37, 42, 36, 41)	-1.7 ( 23.3 )	-1.0 ( 23.7 )	-19.6 ( 102.1 )	3.2 ( 18.2 )	-9.5 ( 32.3 )
PR Week 48 (37, 38, 40, 33, 40)	2.6 ( 33.7 )	17.5 ( 128.8 )	4.0 ( 163.0 )	0.8 ( 18.9 )	-2.8 ( 26.5 )
QRS Week 12 (40, 38, 42, 36, 41)	2.6 ( 22.3 )	-2.9 ( 10.8 )	-1.8 ( 7.6 )	-0.2 ( 5.4 )	6.1 ( 42.8 )
QRS Week 48 (38, 38, 40, 33, 40)	5.6 ( 21.4 )	-1.5 ( 16.1 )	-4.0 ( 13.0 )	0.6 ( 16.2 )	0.1 ( 18.7 )
QT Week 12 (40, 38, 42, 36, 41)	-2.0 ( 46.6 )	1.7 ( 34.0 )	9.5 ( 21.4 )	3.8 ( 25.6 )	11.5 ( 80.8 )
QT Week 48 (38, 38, 40, 33, 40)	-0.7 ( 33.4 )	3.1 ( 29.9 )	3.9 ( 22.8 )	5.4 ( 26.7 )	0.7 ( 31.6 )
RR Week 12 (39, 36, 42, 34, 41)	3.3 ( 99.3 )	-22.5 ( 212.6 )	75.8 ( 179.3 )	11.0 ( 125.1 )	-17.0 ( 182.1 )
RR Week 48 (37, 36, 40, 31, 40)	-0.6 ( 116.1 )	11.9 ( 187.1 )	65.2 ( 139.0 )	44.3 ( 124.0 )	25.1 ( 148.5 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

End point description

Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils were measured in number of white blood cells per liter (10^9/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: 10^9 white blood cells per liter
arithmetic mean (standard deviation)
Basophils Week 1 (41, 38, 43, 41, 40)	0.000 ( 0.0387 )	0.000 ( 0.0329 )	-0.002 ( 0.0408 )	0.007 ( 0.0264 )	0.008 ( 0.0350 )
Basophils Week 2 (42, 38, 43, 41, 41)	0.002 ( 0.0269 )	0.003 ( 0.0283 )	0.000 ( 0.0488 )	0.000 ( 0.0316 )	0.005 ( 0.0384 )
Basophils Week 4 (41, 38, 42, 41, 41)	0.002 ( 0.0474 )	0.005 ( 0.0324 )	-0.007 ( 0.0463 )	0.005 ( 0.0312 )	0.005 ( 0.0312 )
Basophils Week 8 (41, 39, 41, 38, 41)	-0.002 ( 0.0353 )	0.000 ( 0.0229 )	-0.005 ( 0.0384 )	0.003 ( 0.0367 )	0.002 ( 0.0418 )
Basophils Week 12 (41, 39, 43, 38, 41)	0.002 ( 0.0353 )	0.003 ( 0.0280 )	-0.002 ( 0.0462 )	0.000 ( 0.0329 )	0.010 ( 0.0374 )
Basophils Week 16 (42, 38, 42, 38, 40)	0.010 ( 0.0431 )	0.005 ( 0.0324 )	-0.007 ( 0.0463 )	0.000 ( 0.0329 )	0.008 ( 0.0417 )
Basophils Week 20 (39, 39, 41, 37, 39)	-0.003 ( 0.0362 )	0.003 ( 0.0362 )	0.000 ( 0.0500 )	0.005 ( 0.0329 )	0.000 ( 0.0397 )
Basophils Week 24 (39, 38, 40, 36, 40)	0.000 ( 0.0397 )	0.005 ( 0.0324 )	-0.003 ( 0.0530 )	0.008 ( 0.0368 )	0.005 ( 0.0389 )
Basophils Week 28 (39, 38, 40, 35, 40)	0.005 ( 0.0394 )	0.000 ( 0.0329 )	0.008 ( 0.0526 )	0.011 ( 0.0323 )	0.005 ( 0.0450 )
Basophils Week 32 (39, 39, 40, 34, 39)	0.000 ( 0.0324 )	0.005 ( 0.0320 )	-0.010 ( 0.0441 )	0.009 ( 0.0379 )	0.010 ( 0.0384 )
Basophils Week 36 (37, 38, 41, 33, 39)	0.000 ( 0.0408 )	0.003 ( 0.0283 )	-0.002 ( 0.0474 )	0.012 ( 0.0415 )	0.013 ( 0.0409 )
Basophils Week 40 (36, 38, 40, 34, 38)	0.003 ( 0.0506 )	0.005 ( 0.0399 )	-0.010 ( 0.0379 )	0.006 ( 0.0343 )	0.000 ( 0.0403 )
Basophils Week 44 (36, 37, 41, 34, 36)	0.006 ( 0.0410 )	0.003 ( 0.0372 )	0.000 ( 0.0387 )	0.006 ( 0.0422 )	0.000 ( 0.0338 )
Basophils Week 48 (38, 36, 40, 32, 39)	-0.005 ( 0.0462 )	0.003 ( 0.291 )	-0.010 ( 0.0441 )	0.006 ( 0.0354 )	0.000 ( 0.0324 )
Eosinophils Week 1 (41, 38, 43, 41, 40)	0.010 ( 0.0860 )	0.016 ( 0.0718 )	-0.002 ( 0.0801 )	-0.005 ( 0.0999 )	0.017 ( 0.0636 )
Eosinophils Week 2 (42, 38, 43, 41, 41)	0.005 ( 0.0731 )	0.013 ( 0.0777 )	0.002 ( 0.0913 )	0.002 ( 0.0880 )	0.029 ( 0.0929 )
Eosinophils Week 4 (41, 38, 42, 41, 41)	0.002 ( 0.0987 )	0.016 ( 0.0594 )	0.002 ( 0.0780 )	0.005 ( 0.0999 )	0.027 ( 0.0895 )
Eosinophils Week 8 (41, 39, 41, 38, 41)	0.024 ( 0.0969 )	-0.003 ( 0.0707 )	0.000 ( 0.1000 )	0.008 ( 0.0941 )	0.005 ( 0.0669 )
Eosinophils Week 12 (41, 39, 43, 38, 41)	0.020 ( 0.0954 )	0.010 ( 0.0882 )	0.002 ( 0.0831 )	-0.026 ( 0.1155 )	0.017 ( 0.0704 )
Eosinophils Week 16 (42, 38, 42, 38, 40)	0.045 ( 0.1253 )	0.021 ( 0.0935 )	0.010 ( 0.0759 )	-0.005 ( 0.1559 )	0.033 ( 0.0829 )
Eosinophils Week 20 (39, 39, 41, 37, 39)	0.036 ( 0.1038 )	0.026 ( 0.1186 )	0.024 ( 0.1157 )	-0.014 ( 0.1228 )	0.038 ( 0.0935 )
Eosinophils Week 24 (39, 38, 40, 36, 40)	0.031 ( 0.1301 )	0.013 ( 0.0844 )	0.058 ( 0.2111 )	-0.019 ( 0.1238 )	0.037 ( 0.1192 )
Eosinophils Week 28 (39, 38, 40, 35, 40)	0.036 ( 0.0986 )	0.018 ( 0.0926 )	0.053 ( 0.1826 )	-0.000 ( 0.1213 )	0.025 ( 0.0870 )
Eosinophils Week 32 (39, 39, 40, 34, 39)	0.049 ( 0.1502 )	0.033 ( 0.0838 )	0.020 ( 0.1418 )	0.024 ( 0.1577 )	0.041 ( 0.1141 )
Eosinophils Week 36 (37, 38, 41, 33, 39)	0.054 ( 0.1726 )	0.018 ( 0.0955 )	0.022 ( 0.0909 )	0.027 ( 0.1526 )	0.015 ( 0.0961 )
Eosinophils Week 40 (36, 38, 40, 34, 38)	0.050 ( 0.1444 )	0.018 ( 0.0865 )	0.018 ( 0.0958 )	0.015 ( 0.1971 )	0.039 ( 0.1128 )
Eosinophils Week 44 (36, 37, 41, 34, 36)	0.072 ( 0.1523 )	0.019 ( 0.0908 )	0.024 ( 0.0994 )	-0.009 ( 0.1798 )	0.006 ( 0.0893 )
Eosinophils Week 48 (38, 36, 40, 32, 39)	0.045 ( 0.1811 )	0.006 ( 0.0754 )	0.023 ( 0.0891 )	0.009 ( 0.2833 )	-0.005 ( 0.0857 )
Leukocytes Week 1 (41, 38, 43, 41, 40)	-0.271 ( 1.1885 )	-0.597 ( 1.1490 )	-0.656 ( 1.2593 )	-1.029 ( 1.6496 )	-0.285 ( 1.6896 )
Leukocytes Week 2 (42, 39, 43, 41, 41)	0.157 ( 1.3195 )	-0.131 ( 2.1769 )	-0.309 ( 1.3735 )	-0.954 ( 2.0441 )	-0.322 ( 1.5501 )
Leukocytes Week 4 (41, 38, 42, 41, 41)	-0.049 ( 1.1938 )	-0.411 ( 1.1988 )	-0.336 ( 1.5088 )	-1.017 ( 1.9397 )	-0.656 ( 1.4264 )
Leukocytes Week 8 (41, 39, 41, 38, 41)	0.429 ( 1.7036 )	-0.333 ( 1.4014 )	-0.185 ( 1.2889 )	-1.071 ( 1.9639 )	-0.629 ( 1.5489 )
Leukocytes Week 12 (41, 39, 43, 38, 41)	0.190 ( 1.6223 )	-0.438 ( 1.3854 )	-0.495 ( 1.6904 )	-0.997 ( 2.1806 )	-0.634 ( 1.6084 )
Leukocytes Week 16 (42, 38, 42, 38, 40)	-0.400 ( 1.5616 )	-0.839 ( 1.8179 )	-0.590 ( 1.4668 )	-1.318 ( 2.3324 )	-0.293 ( 1.8427 )
Leukocytes Week 20 (39, 39, 41, 37, 40)	-0.936 ( 1.2756 )	-1.100 ( 1.5599 )	-0.432 ( 1.3032 )	-0.932 ( 2.2832 )	-0.455 ( 1.7116 )
Leukocytes Week 24 (39, 38, 40, 36, 40)	-1.251 ( 1.3888 )	-0.884 ( 1.7768 )	-0.495 ( 1.4216 )	-1.119 ( 2.2807 )	-0.765 ( 1.8691 )
Leukocytes Week 28 (39, 38, 41, 35, 40)	-0.700 ( 1.8180 )	-0.316 ( 2.3086 )	-0.100 ( 1.4942 )	-0.894 ( 1.7119 )	-0.342 ( 1.5683 )
Leukocytes Week 32 (39, 39, 40, 34, 39)	-0.762 ( 1.4273 )	-0.862 ( 2.0091 )	-0.330 ( 1.5750 )	-0.918 ( 2.6184 )	-0.505 ( 1.4800 )
Leukocytes Week 36 (37, 38, 41, 33, 39)	-0.541 ( 1.5971 )	-0.974 ( 1.7389 )	-0.366 ( 1.4549 )	-1.082 ( 2.3389 )	-0.126 ( 2.2565 )
Leukocytes Week 40 (36, 38, 41, 34, 38)	-0.783 ( 1.7693 )	-0.826 ( 1.5942 )	-0.437 ( 1.7878 )	-1.226 ( 2.3856 )	-0.266 ( 1.7976 )
Leukocytes Week 44 (37, 37, 41, 34, 36)	-1.065 ( 1.6070 )	-0.978 ( 1.8151 )	-0.537 ( 1.5641 )	-1.032 ( 2.1585 )	-0.825 ( 1.8917 )
Leukocytes Week 48 (38, 36, 40, 32, 39)	-0.739 ( 1.7774 )	-0.869 ( 1.7109 )	-0.473 ( 1.7104 )	-1.225 ( 2.5952 )	-0.777 ( 1.8593 )
Lymphocytes Week 1 (41, 38, 43, 41, 40)	-0.083 ( 0.5074 )	-0.024 ( 0.4142 )	0.044 ( 0.5039 )	-0.017 ( 0.4189 )	0.020 ( 0.3006 )
Lymphocytes Week 2 (42, 38, 43, 41, 41)	0.105 ( 0.3246 )	0.026 ( 0.4137 )	0.021 ( 0.6006 )	0.007 ( 0.3643 )	0.161 ( 0.4277 )
Lymphocytes Week 4 (41, 38, 42, 41, 41)	0.037 ( 0.4386 )	0.024 ( 0.3259 )	0.010 ( 0.6003 )	-0.032 ( 0.3996 )	0.095 ( 0.3263 )
Lymphocytes Week 8 (41, 39, 41, 38, 41)	0.120 ( 0.3776 )	0.054 ( 0.3783 )	0.063 ( 0.5928 )	0.053 ( 0.4980 )	0.129 ( 0.3939 )
Lymphocytes Week 12 (41, 39, 43, 38, 41)	0.041 ( 0.3647 )	0.051 ( 0.4167 )	0.000 ( 0.5640 )	-0.047 ( 0.3703 )	0.061 ( 0.3301 )
Lymphocytes Week 16 (42, 38, 42, 38, 40)	0.052 ( 0.5567 )	0.071 ( 0.3571 )	0.026 ( 0.5539 )	-0.029 ( 0.4991 )	0.135 ( 0.4197 )
Lymphocytes Week 20 (39, 39, 41, 37, 39)	0.003 ( 0.4934 )	0.008 ( 0.3970 )	0.149 ( 0.4675 )	-0.035 ( 0.4566 )	0.126 ( 0.4216 )
Lymphocytes Week 24 (39, 38, 40, 36, 40)	-0.041 ( 0.3905 )	0.050 ( 0.3630 )	0.048 ( 0.4455 )	-0.036 ( 0.3788 )	0.053 ( 0.3974 )
Lymphocytes Week 28 (39, 38, 40, 35, 40)	0.036 ( 0.5869 )	0.105 ( 0.3594 )	0.210 ( 0.5999 )	0.103 ( 0.5544 )	0.172 ( 0.3776 )
Lymphocytes Week 32 (39, 39, 40, 34, 39)	-0.000 ( 0.5109 )	0.103 ( 0.4233 )	0.083 ( 0.6524 )	0.112 ( 0.5056 )	0.146 ( 0.3966 )
Lymphocytes Week 36 (37, 38, 41, 33, 39)	0.078 ( 0.4894 )	0.039 ( 0.4227 )	0.134 ( 0.5673 )	0.103 ( 0.5491 )	0.118 ( 0.3810 )
Lymphocytes Week 40 (36, 38, 40, 34, 38)	0.139 ( 0.4871 )	0.168 ( 0.4281 )	0.120 ( 0.6018 )	0.038 ( 0.4335 )	0.176 ( 0.3709 )
Lymphocytes Week 44 (36, 37, 41, 34, 36)	-0.008 ( 0.5390 )	0.105 ( 0.4136 )	0.124 ( 0.5366 )	0.115 ( 0.4881 )	0.153 ( 0.4462 )
Lymphocytes Week 48 (38, 36, 40, 32, 39)	0.066 ( 0.5313 )	0.103 ( 0.3645 )	0.078 ( 0.5041 )	0.019 ( 0.3763 )	0.072 ( 0.3755 )
Monocytes Week 1 (41, 38, 43, 41, 40)	0.007 ( 0.2184 )	-0.008 ( 0.1477 )	-0.012 ( 0.1679 )	-0.088 ( 0.2315 )	-0.027 ( 0.1724 )
Monocytes Week 2 (42, 38, 43, 41, 41)	0.076 ( 0.1358 )	-0.011 ( 0.1673 )	0.014 ( 0.1897 )	-0.095 ( 0.2701 )	-0.010 ( 0.1882 )
Monocytes Week 4 (41, 38, 42, 41, 41)	0.032 ( 0.1588 )	-0.021 ( 0.1473 )	-0.040 ( 0.1862 )	-0.066 ( 0.2404 )	-0.085 ( 0.1459 )
Monocytes Week 8 (41, 39, 41, 38, 41)	0.059 ( 0.1910 )	-0.041 ( 0.1743 )	0.005 ( 0.1580 )	-0.103 ( 0.2520 )	-0.071 ( 0.1834 )
Monocytes Week 12 (41, 39, 43, 38, 41)	0.020 ( 0.1913 )	-0.031 ( 0.1608 )	-0.033 ( 0.1686 )	-0.105 ( 0.2630 )	-0.059 ( 0.1414 )
Monocytes Week 16 (42, 38, 42, 38, 40)	-0.007 ( 0.1629 )	-0.050 ( 0.1673 )	-0.024 ( 0.1265 )	-0.079 ( 0.2384 )	-0.043 ( 0.1752 )
Monocytes Week 20 (39, 39, 41, 37, 39)	-0.008 ( 0.1783 )	-0.041 ( 0.1534 )	-0.015 ( 0.1509 )	-0.081 ( 0.2448 )	-0.003 ( 0.1899 )
Monocytes Week 24 (39, 38, 40, 36, 40)	-0.026 ( 0.1292 )	-0.034 ( 0.1361 )	0.003 ( 0.1476 )	-0.056 ( 0.2602 )	-0.027 ( 0.1921 )
Monocytes Week 28 (39, 38, 40, 35, 40)	0.026 ( 0.2087 )	0.042 ( 0.1981 )	0.055 ( 0.1724 )	-0.029 ( 0.2729 )	-0.012 ( 0.1911 )
Monocytes Week 32 (39, 39, 40, 34, 39)	0.064 ( 0.2356 )	-0.005 ( 0.1731 )	-0.003 ( 0.1271 )	-0.035 ( 0.2684 )	0.010 ( 0.1744 )
Monocytes Week 36 (37, 38, 41, 33, 39)	0.054 ( 0.1626 )	-0.024 ( 0.1792 )	0.032 ( 0.1404 )	-0.036 ( 0.2644 )	0.049 ( 0.2327 )
Monocytes Week 40 (36, 38, 40, 34, 38)	0.053 ( 0.1647 )	0.008 ( 0.1323 )	0.020 ( 0.1636 )	-0.059 ( 0.2830 )	-0.018 ( 0.1504 )
Monocytes Week 44 (36, 37, 41, 34, 36)	0.019 ( 0.1939 )	-0.008 ( 0.1588 )	0.044 ( 0.1644 )	-0.032 ( 0.2446 )	-0.019 ( 0.2202 )
Monocytes Week 48 (38, 36, 40, 32, 39)	0.021 ( 0.2145 )	0.000 ( 0.1707 )	-0.013 ( 0.1399 )	-0.078 ( 0.2511 )	-0.077 ( 0.1709 )
Neutrophils Week 1 (41, 38, 43, 41, 40)	-0.200 ( 1.0959 )	-0.558 ( 0.9627 )	-0.693 ( 1.2971 )	-0.934 ( 1.4768 )	-0.325 ( 1.5720 )
Neutrophils Week 2 (42, 38, 43, 41, 41)	-0.026 ( 1.1945 )	-0.418 ( 1.1627 )	-0.337 ( 1.3109 )	-0.880 ( 1.8457 )	-0.537 ( 1.3989 )
Neutrophils Week 4 (41, 38, 42, 41, 41)	-0.102 ( 1.0044 )	-0.405 ( 1.1246 )	-0.290 ( 1.3463 )	-0.924 ( 1.9975 )	-0.732 ( 1.4028 )
Neutrophils Week 8 (41, 39, 41, 38, 41)	0.249 ( 1.5358 )	-0.346 ( 1.2640 )	-0.256 ( 1.3898 )	-1.021 ( 1.7129 )	-0.717 ( 1.4589 )
Neutrophils Week 12 (41, 39, 43, 38, 41)	0.117 ( 1.5103 )	-0.456 ( 1.1227 )	-0.458 ( 1.6879 )	-0.832 ( 2.2192 )	-0.673 ( 1.3887 )
Neutrophils Week 16 (42, 38, 42, 38, 40)	-0.490 ( 1.6866 )	-0.879 ( 1.5752 )	-0.617 ( 1.6027 )	-1.203 ( 2.2840 )	-0.448 ( 1.6816 )
Neutrophils Week 20 (39, 39, 41, 37, 39)	-0.972 ( 1.2085 )	-1.069 ( 1.4219 )	-0.595 ( 1.4319 )	-0.827 ( 2.2663 )	-0.618 ( 1.5716 )
Neutrophils Week 24 (39, 38, 40, 36, 40)	-1.210 ( 1.4067 )	-0.895 ( 1.6288 )	-0.593 ( 1.5309 )	-1.011 ( 2.2968 )	-0.850 ( 1.6461 )
Neutrophils Week 28 (39, 38, 40, 35, 40)	-0.774 ( 1.8189 )	-0.484 ( 2.2620 )	-0.555 ( 1.2608 )	-0.949 ( 1.7676 )	-0.568 ( 1.3889 )
Neutrophils Week 32 (39, 39, 40, 34, 39)	-0.869 ( 1.2796 )	-0.969 ( 1.8241 )	-0.433 ( 1.7889 )	-1.038 ( 2.4800 )	-0.718 ( 1.4299 )
Neutrophils Week 36 (37, 38, 41, 33, 39)	-0.722 ( 1.6422 )	-0.992 ( 1.6583 )	-0.541 ( 1.5519 )	-1.185 ( 2.1881 )	-0.354 ( 2.1441 )
Neutrophils Week 40 (36, 38, 40, 34, 38)	-1.006 ( 1.7393 )	-0.992 ( 1.4740 )	-0.575 ( 1.9567 )	-1.229 ( 2.4065 )	-0.495 ( 1.5857 )
Neutrophils Week 44 (36, 37, 41, 34, 36)	-0.978 ( 1.2444 )	-1.086 ( 1.6049 )	-0.717 ( 1.6966 )	-1.109 ( 2.2673 )	-0.983 ( 1.6556 )
Neutrophils Week 48 (38, 36, 40, 32, 39)	-0.861 ( 1.6858 )	-0.939 ( 1.5670 )	-0.558 ( 1.7944 )	-1.178 ( 2.6503 )	-0.805 ( 1.6631 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

End point description

Erythrocytes mean corpuscular hemoglobin concentration (MCHC) and hemoglobin were measured in grams per liter (g/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: g/L
arithmetic mean (standard deviation)
MCHC Week 1 (41, 38, 43, 41, 40)	-2.293 ( 8.4594 )	0.789 ( 8.9719 )	-1.860 ( 8.0551 )	0.927 ( 9.1088 )	1.200 ( 12.2395 )
MCHC Week 2 (42, 39, 43, 41, 41)	-2.310 ( 7.9923 )	2.564 ( 9.8216 )	0.465 ( 8.4778 )	0.707 ( 8.6263 )	2.854 ( 10.1822 )
MCHC Week 4 (41, 38, 42, 41, 41)	-3.927 ( 10.0633 )	1.474 ( 10.5849 )	-2.500 ( 11.5045 )	-0.878 ( 9.4026 )	1.756 ( 11.8697 )
MCHC Week 8 (41, 39, 41, 38, 41)	-5.195 ( 11.7158 )	-1.897 ( 11.3249 )	-3.780 ( 10.7576 )	-3.079 ( 10.7033 )	0.610 ( 12.7493 )
MCHC Week 12 (41, 39, 43, 38, 41)	-7.927 ( 14.6704 )	-3.179 ( 13.4122 )	-3.907 ( 11.5404 )	-2.684 ( 9.4099 )	1.732 ( 13.3959 )
MCHC Week 16 (42, 38, 42, 38, 40)	-6.286 ( 12.3393 )	-3.000 ( 14.5751 )	-5.262 ( 12.1917 )	-1.026 ( 11.6816 )	-0.700 ( 16.1026 )
MCHC Week 20 (40, 39, 41, 37, 40)	-5.050 ( 12.8102 )	0.923 ( 11.8108 )	-1.902 ( 12.8078 )	0.919 ( 8.7349 )	0.200 ( 16.1725 )
MCHC Week 24 (39, 38, 40, 36, 40)	1.000 ( 10.9232 )	4.132 ( 10.3849 )	-0.625 ( 14.6685 )	4.583 ( 11.3121 )	4.250 ( 13.4064 )
MCHC Week 28 (39, 38, 41, 35, 40)	2.179 ( 10.3285 )	4.658 ( 9.6906 )	1.707 ( 9.9505 )	4.400 ( 13.7524 )	6.150 ( 12.5382 )
MCHC Week 32 (39, 39, 40, 34, 39)	6.308 ( 9.7796 )	10.231 ( 9.5957 )	4.850 ( 11.3692 )	7.971 ( 12.3497 )	10.462 ( 12.9855 )
MCHC Week 36 (38, 38, 41, 33, 39)	5.500 ( 9.7779 )	10.921 ( 10.2229 )	2.732 ( 12.4097 )	6.788 ( 12.2034 )	9.462 ( 12.7998 )
MCHC Week 40 (37, 38, 41, 34, 38)	3.108 ( 9.8736 )	8.237 ( 12.0706 )	4.976 ( 11.5639 )	9.088 ( 11.5480 )	9.079 ( 11.5393 )
MCHC Week 44 (37, 38, 41, 34, 36)	6.297 ( 10.6975 )	7.289 ( 12.6254 )	3.415 ( 12.6293 )	6.353 ( 14.3038 )	9.278 ( 12.8076 )
MCHC Week 48 (38, 37, 41, 33, 40)	5.079 ( 10.4916 )	7.216 ( 9.3812 )	2.122 ( 11.8769 )	5.394 ( 12.9300 )	8.250 ( 11.3448 )
Hemoglobin Week 1 (41, 38, 43, 41, 40)	-4.854 ( 5.6726 )	0.000 ( 5.6569 )	1.302 ( 5.1480 )	0.512 ( 6.0462 )	-0.875 ( 4.8368 )
Hemoglobin Week 2 (42, 39, 43, 41, 41)	-4.810 ( 6.5154 )	-0.359 ( 5.2339 )	0.070 ( 6.5915 )	-1.561 ( 6.7047 )	0.317 ( 5.3499 )
Hemoglobin Week 4 (41, 38, 42, 41, 41)	-4.390 ( 7.5162 )	0.895 ( 7.6434 )	0.881 ( 6.4551 )	0.512 ( 5.7189 )	1.195 ( 5.8916 )
Hemoglobin Week 8 (41, 39, 41, 38, 41)	-4.561 ( 7.0995 )	0.308 ( 7.0865 )	2.195 ( 7.7628 )	0.553 ( 6.8010 )	1.195 ( 7.4439 )
Hemoglobin Week 12 (41, 39, 43, 38, 41)	-5.220 ( 6.7879 )	0.692 ( 7.7601 )	2.488 ( 7.6512 )	0.868 ( 7.3344 )	2.488 ( 8.2344 )
Hemoglobin Week 16 (42, 38, 42, 38, 40)	-1.619 ( 6.4768 )	2.579 ( 8.3880 )	1.524 ( 8.7853 )	1.737 ( 7.3547 )	3.125 ( 7.7400 )
Hemoglobin Week 20 (40, 39, 41, 37, 40)	-0.400 ( 7.3233 )	2.667 ( 8.6764 )	2.268 ( 6.9822 )	1.892 ( 7.6186 )	2.925 ( 7.7207 )
Hemoglobin Week 24 (39, 38, 40, 36, 40)	0.564 ( 8.1879 )	3.658 ( 9.0622 )	4.075 ( 8.0714 )	2.000 ( 6.6462 )	3.425 ( 6.2834 )
Hemoglobin Week 28 (39, 38, 41, 35, 40)	-1.513 ( 8.0259 )	3.342 ( 8.9511 )	3.122 ( 8.6261 )	0.857 ( 7.2645 )	3.400 ( 8.6730 )
Hemoglobin Week 32 (39, 39, 40, 34, 39)	-0.282 ( 8.2684 )	4.487 ( 8.3094 )	4.300 ( 9.4032 )	2.118 ( 7.4254 )	5.615 ( 8.6378 )
Hemoglobin Week 36 (38, 38, 41, 33, 39)	0.947 ( 9.1738 )	6.053 ( 8.1405 )	4.293 ( 9.5766 )	3.818 ( 7.3334 )	4.949 ( 8.4851 )
Hemoglobin Week 40 (37, 38, 41, 34, 38)	1.432 ( 9.1090 )	5.868 ( 8.7863 )	4.317 ( 9.6552 )	3.618 ( 7.8277 )	4.132 ( 7.7987 )
Hemoglobin Week 44 (37, 38, 41, 34, 36)	1.486 ( 10.1040 )	5.000 ( 9.2998 )	3.659 ( 9.1750 )	4.912 ( 8.5895 )	4.722 ( 8.5511 )
Hemoglobin Week 48 (38, 37, 41, 33, 40)	2.474 ( 9.7002 )	5.270 ( 9.1974 )	3.780 ( 9.9210 )	4.030 ( 9.2550 )	4.725 ( 7.3554 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB))

Top of page

End point title

Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB))

End point description

Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: picograms (pg)
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-0.073 ( 0.4980 )	0.058 ( 0.4624 )	-0.049 ( 0.4050 )	0.073 ( 0.3975 )	-0.055 ( 0.4455 )
Week 2 (42, 39, 43, 41, 41)	-0.050 ( 0.3890 )	0.126 ( 0.5149 )	0.023 ( 0.4225 )	0.066 ( 0.4357 )	0.085 ( 0.4287 )
Week 4 (41, 38, 42, 41, 41)	-0.112 ( 0.5501 )	0.089 ( 0.5584 )	0.060 ( 0.5910 )	0.012 ( 0.4691 )	0.066 ( 0.6085 )
Week 8 (41, 39, 41, 38, 41)	-0.110 ( 0.6778 )	0.141 ( 0.6801 )	0.007 ( 0.5926 )	0.034 ( 0.6851 )	0.095 ( 0.7994 )
Week 12 (41, 39, 43, 38, 41)	-0.285 ( 0.6770 )	0.023 ( 0.7253 )	0.091 ( 0.8358 )	-0.132 ( 0.8335 )	0.039 ( 1.0454 )
Week 16 (42, 38, 42, 38, 40)	-0.233 ( 0.7281 )	0.097 ( 0.8824 )	0.014 ( 0.9236 )	-0.118 ( 0.8440 )	-0.067 ( 1.1713 )
Week 20 (40, 39, 41, 37, 40)	-0.290 ( 0.8145 )	-0.033 ( 0.9172 )	0.029 ( 0.9819 )	-0.035 ( 0.7013 )	0.075 ( 1.0824 )
Week 24 (39, 38, 40, 36, 40)	-0.249 ( 1.0443 )	0.108 ( 0.9947 )	-0.057 ( 1.1804 )	-0.097 ( 0.7284 )	-0.007 ( 1.2338 )
Week 28 (39, 38, 41, 35, 40)	-0.103 ( 1.0101 )	0.029 ( 0.7241 )	-0.122 ( 1.1130 )	-0.211 ( 0.8277 )	0.020 ( 1.2950 )
Week 32 (39, 39, 40, 34, 39)	0.003 ( 1.2619 )	0.297 ( 0.8561 )	0.058 ( 1.1522 )	0.026 ( 0.7684 )	0.167 ( 1.2472 )
Week 36 (38, 38, 41, 33, 39)	-0.082 ( 1.3242 )	0.237 ( 0.8722 )	-0.093 ( 1.0792 )	-0.248 ( 0.8581 )	0.118 ( 1.1473 )
Week 40 (37, 38, 41, 34, 38)	-0.170 ( 1.3453 )	0.134 ( 0.8960 )	-0.134 ( 1.2095 )	-0.147 ( 0.8645 )	0.034 ( 1.0839 )
Week 44 (37, 38, 41, 34, 36)	0.097 ( 1.3103 )	0.129 ( 0.8742 )	-0.080 ( 1.1771 )	-0.159 ( 0.7480 )	0.108 ( 1.2532 )
Week 48 (38, 37, 41, 33, 40)	0.137 ( 1.4139 )	0.178 ( 0.9369 )	-0.120 ( 1.1279 )	-0.030 ( 0.7888 )	0.140 ( 1.2161 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular volume)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular volume)

End point description

Erythrocytes mean corpuscular volume was measured in femtolitres (fL). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: femtolitres (fL)
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	0.422 ( 1.8855 )	-0.087 ( 1.9540 )	0.386 ( 2.2542 )	-0.017 ( 2.1066 )	-0.510 ( 2.7686 )
Week 2 (42, 39, 43, 41, 41)	0.450 ( 1.8867 )	-0.362 ( 2.1689 )	-0.021 ( 1.8767 )	-0.039 ( 2.3876 )	-0.549 ( 2.5751 )
Week 4 (41, 38, 42, 41, 41)	0.829 ( 2.3409 )	-0.163 ( 2.4631 )	0.945 ( 3.2325 )	0.354 ( 2.8851 )	-0.259 ( 2.5328 )
Week 8 (41, 39, 41, 38, 41)	1.163 ( 3.6524 )	0.938 ( 2.9445 )	1.110 ( 3.0283 )	0.916 ( 3.0058 )	0.090 ( 3.5125 )
Week 12 (41, 39, 43, 38, 41)	1.478 ( 3.9560 )	0.951 ( 3.4617 )	1.367 ( 3.8471 )	0.342 ( 3.1129 )	-0.390 ( 3.3907 )
Week 16 (42, 38, 42, 38, 40)	1.107 ( 3.4022 )	1.168 ( 3.7760 )	1.571 ( 4.3326 )	-0.016 ( 3.6944 )	0.048 ( 4.4345 )
Week 20 (40, 39, 41, 37, 40)	0.497 ( 3.5197 )	-0.349 ( 2.8975 )	0.649 ( 3.7758 )	-0.338 ( 2.5959 )	0.202 ( 4.2993 )
Week 24 (39, 38, 40, 36, 40)	-1.033 ( 2.9007 )	-0.858 ( 2.1793 )	0.143 ( 4.9985 )	-1.522 ( 3.1692 )	-1.195 ( 3.5759 )
Week 28 (39, 38, 41, 35, 40)	-0.910 ( 2.6477 )	-1.184 ( 2.3264 )	-0.754 ( 3.3662 )	-1.854 ( 3.6605 )	-1.638 ( 3.3447 )
Week 32 (39, 39, 40, 34, 39)	-1.654 ( 2.7565 )	-1.851 ( 2.4024 )	-1.075 ( 3.5390 )	-2.071 ( 3.7652 )	-2.351 ( 3.1052 )
Week 36 (38, 38, 41, 33, 39)	-1.724 ( 3.1037 )	-2.266 ( 2.3516 )	-0.912 ( 3.9627 )	-2.558 ( 3.8468 )	-2.236 ( 3.2869 )
Week 40 (37, 38, 41, 34, 38)	-1.386 ( 2.8575 )	-1.882 ( 3.1285 )	-1.698 ( 3.0263 )	-2.885 ( 3.1443 )	-2.421 ( 2.9445 )
Week 44 (37, 38, 41, 34, 36)	-1.405 ( 3.4627 )	-1.632 ( 3.4207 )	-1.117 ( 3.4616 )	-2.171 ( 4.4367 )	-2.186 ( 3.4915 )
Week 48 (38, 37, 41, 33, 40)	-0.942 ( 3.5913 )	-1.492 ( 2.5065 )	-0.846 ( 3.1243 )	-1.527 ( 3.6540 )	-1.788 ( 3.5554 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (erythrocytes)

End point description

Erythrocytes was measured in number of red blood cells per liter (10^12/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: 10^12 red blood cells per liter
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-0.148 ( 0.2071 )	-0.008 ( 0.1927 )	0.050 ( 0.1773 )	0.008 ( 0.2109 )	-0.017 ( 0.1609 )
Week 2 (42, 39, 43, 41, 41)	-0.149 ( 0.2244 )	-0.029 ( 0.1788 )	-0.004 ( 0.2280 )	-0.063 ( 0.2236 )	0.000 ( 0.1809 )
Week 4 (41, 38, 42, 41, 41)	-0.132 ( 0.2780 )	0.018 ( 0.2535 )	0.023 ( 0.2135 )	0.013 ( 0.1955 )	0.031 ( 0.2065 )
Week 8 (41, 39, 41, 38, 41)	-0.135 ( 0.2546 )	-0.011 ( 0.2206 )	0.074 ( 0.2466 )	0.014 ( 0.2190 )	0.026 ( 0.2264 )
Week 12 (41, 39, 43, 38, 41)	-0.131 ( 0.2678 )	0.021 ( 0.2561 )	0.069 ( 0.2419 )	0.051 ( 0.2243 )	0.075 ( 0.2393 )
Week 16 (42, 38, 42, 38, 40)	-0.020 ( 0.2375 )	0.075 ( 0.2898 )	0.047 ( 0.2810 )	0.074 ( 0.2255 )	0.110 ( 0.2533 )
Week 20 (40, 39, 41, 37, 40)	0.036 ( 0.2618 )	0.096 ( 0.2855 )	0.068 ( 0.2089 )	0.064 ( 0.2273 )	0.081 ( 0.2191 )
Week 24 (39, 38, 40, 36, 40)	0.059 ( 0.2639 )	0.110 ( 0.2974 )	0.142 ( 0.2573 )	0.074 ( 0.2250 )	0.110 ( 0.1931 )
Week 28 (39, 38, 41, 35, 40)	-0.034 ( 0.2453 )	0.108 ( 0.2681 )	0.122 ( 0.2445 )	0.058 ( 0.2359 )	0.106 ( 0.2567 )
Week 32 (39, 39, 40, 34, 39)	-0.010 ( 0.2461 )	0.104 ( 0.2660 )	0.133 ( 0.2716 )	0.061 ( 0.2555 )	0.156 ( 0.2714 )
Week 36 (38, 38, 41, 33, 39)	0.044 ( 0.2524 )	0.166 ( 0.2542 )	0.156 ( 0.2849 )	0.161 ( 0.2399 )	0.145 ( 0.2377 )
Week 40 (37, 38, 41, 34, 38)	0.079 ( 0.2682 )	0.177 ( 0.2733 )	0.163 ( 0.2736 )	0.141 ( 0.2535 )	0.129 ( 0.2403 )
Week 44 (37, 38, 41, 34, 36)	0.035 ( 0.2645 )	0.146 ( 0.2846 )	0.133 ( 0.2622 )	0.188 ( 0.2933 )	0.135 ( 0.2128 )
Week 48 (38, 37, 41, 33, 40)	0.061 ( 0.2693 )	0.146 ( 0.2994 )	0.141 ( 0.2747 )	0.135 ( 0.2934 )	0.129 ( 0.2354 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (hematocrit)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (hematocrit)

End point description

Hematocrit was measured in volume percentage (%) of red blood cells in blood. The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: volume % of red blood cells
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-0.011 ( 0.0189 )	-0.001 ( 0.0211 )	0.007 ( 0.0181 )	0.000 ( 0.0206 )	-0.004 ( 0.0206 )
Week 2 (42, 39, 43, 41, 41)	-0.011 ( 0.0230 )	-0.004 ( 0.0204 )	-0.000 ( 0.0205 )	-0.006 ( 0.0220 )	-0.003 ( 0.0174 )
Week 4 (41, 38, 42, 41, 41)	-0.008 ( 0.0254 )	0.001 ( 0.0211 )	0.006 ( 0.0220 )	0.003 ( 0.0190 )	0.001 ( 0.0209 )
Week 8 (41, 39, 41, 38, 41)	-0.007 ( 0.0239 )	0.003 ( 0.0244 )	0.012 ( 0.0237 )	0.005 ( 0.0208 )	0.003 ( 0.0232 )
Week 12 (41, 39, 43, 38, 41)	-0.005 ( 0.0287 )	0.007 ( 0.0281 )	0.013 ( 0.0276 )	0.006 ( 0.0219 )	0.005 ( 0.0231 )
Week 16 (42, 38, 42, 38, 40)	0.004 ( 0.0202 )	0.012 ( 0.0259 )	0.011 ( 0.0254 )	0.006 ( 0.0240 )	0.010 ( 0.0252 )
Week 20 (40, 39, 41, 37, 40)	0.006 ( 0.0217 )	0.007 ( 0.0270 )	0.010 ( 0.0211 )	0.004 ( 0.0241 )	0.008 ( 0.0246 )
Week 24 (39, 38, 40, 36, 40)	0.001 ( 0.0192 )	0.006 ( 0.0253 )	0.014 ( 0.0256 )	-0.000 ( 0.0222 )	0.005 ( 0.0219 )
Week 28 (39, 38, 41, 35, 40)	-0.007 ( 0.0210 )	0.004 ( 0.0248 )	0.008 ( 0.0241 )	-0.003 ( 0.0229 )	0.002 ( 0.0238 )
Week 32 (39, 39, 40, 34, 39)	-0.009 ( 0.0207 )	0.000 ( 0.0249 )	0.007 ( 0.0225 )	-0.004 ( 0.0196 )	0.003 ( 0.0248 )
Week 36 (38, 38, 41, 33, 39)	-0.004 ( 0.0222 )	0.004 ( 0.0228 )	0.009 ( 0.0258 )	0.003 ( 0.0221 )	0.003 ( 0.0234 )
Week 40 (37, 38, 41, 34, 38)	0.000 ( 0.0231 )	0.007 ( 0.0278 )	0.007 ( 0.0246 )	-0.001 ( 0.0221 )	0.000 ( 0.0206 )
Week 44 (37, 38, 41, 34, 36)	-0.003 ( 0.0272 )	0.006 ( 0.0297 )	0.007 ( 0.0239 )	0.007 ( 0.0246 )	0.002 ( 0.0194 )
Week 48 (38, 37, 41, 33, 40)	0.001 ( 0.0243 )	0.007 ( 0.0257 )	0.009 ( 0.0260 )	0.005 ( 0.0252 )	0.004 ( 0.0212 )

No statistical analyses for this end point

Secondary: Changes from Baseline in hematology parameters during the study (platelets)

Top of page

End point title

Changes from Baseline in hematology parameters during the study (platelets)

End point description

Platelets was measured in number of platelets per liter (10^9/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: 10^9 platelets per liter
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-5.073 ( 30.2609 )	-3.368 ( 25.9515 )	3.209 ( 30.5883 )	-2.098 ( 24.6412 )	-9.325 ( 23.4109 )
Week 2 (42, 39, 42, 41, 41)	4.000 ( 27.3112 )	-5.179 ( 38.2800 )	-3.810 ( 41.8250 )	-15.122 ( 32.8414 )	-15.415 ( 31.7025 )
Week 4 (41, 38, 41, 41, 41)	-3.927 ( 29.6643 )	-6.868 ( 29.7487 )	-13.878 ( 43.7568 )	-19.415 ( 32.6450 )	-27.073 ( 41.9299 )
Week 8 (41, 39, 40, 38, 41)	1.561 ( 29.1042 )	-12.077 ( 28.9876 )	-5.475 ( 44.7718 )	-17.605 ( 29.8442 )	-26.195 ( 44.1719 )
Week 12 (41, 39, 42, 38, 41)	-2.171 ( 32.0795 )	-17.359 ( 35.4308 )	-11.286 ( 40.7451 )	-10.079 ( 44.8977 )	-23.171 ( 47.2995 )
Week 16 (42, 38, 42, 38, 40)	-18.833 ( 50.4844 )	-18.263 ( 37.3259 )	-13.952 ( 50.7173 )	-9.895 ( 35.3246 )	-25.425 ( 37.6556 )
Week 20 (40, 39, 41, 37, 40)	-18.625 ( 50.3988 )	-23.077 ( 39.6534 )	-10.512 ( 48.0755 )	-15.324 ( 28.8329 )	-22.725 ( 42.2502 )
Week 24 (39, 38, 40, 36, 40)	-19.974 ( 49.0196 )	-14.000 ( 37.7760 )	-4.600 ( 49.4025 )	-10.972 ( 36.8375 )	-22.900 ( 47.4092 )
Week 28 (39, 38, 41, 35, 40)	-24.256 ( 51.8001 )	-16.868 ( 40.6635 )	-7.683 ( 47.8155 )	-12.800 ( 30.7904 )	-19.600 ( 42.3052 )
Week 32 (39, 39, 40, 34, 39)	-22.410 ( 51.9553 )	-18.590 ( 41.7226 )	-13.575 ( 51.9304 )	-20.618 ( 38.8969 )	-23.179 ( 42.2018 )
Week 36 (38, 38, 41, 33, 39)	-25.000 ( 52.6990 )	-16.474 ( 46.8844 )	-14.561 ( 50.2106 )	-18.848 ( 40.0563 )	-23.846 ( 45.1340 )
Week 40 (37, 38, 41, 34, 38)	-23.432 ( 53.2747 )	-20.895 ( 41.4845 )	-14.927 ( 51.2652 )	-24.088 ( 33.4133 )	-21.789 ( 46.1467 )
Week 44 (37, 38, 39, 34, 36)	-22.703 ( 57.8383 )	-22.474 ( 41.0627 )	-18.051 ( 49.1646 )	-24.735 ( 38.4710 )	-31.389 ( 48.5306 )
Week 48 (38, 37, 41, 33, 39)	-27.395 ( 56.2963 )	-23.811 ( 47.1150 )	-24.220 ( 46.2458 )	-22.273 ( 37.4243 )	-28.974 ( 42.9960 )

No statistical analyses for this end point

Secondary: Changes from Baseline in biochemistry parameters during the study (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase)

Top of page

End point title

Changes from Baseline in biochemistry parameters during the study (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase)

End point description

Alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH) were measured in units per liter (U/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: U/L
arithmetic mean (standard deviation)
ALT Week 1 (41, 38, 43, 41, 40)	-1.366 ( 12.7451 )	2.526 ( 15.5211 )	2.628 ( 42.1234 )	3.122 ( 10.2791 )	0.700 ( 9.5868 )
ALT Week 2 (42, 39, 43, 41, 41)	-1.714 ( 15.4624 )	2.026 ( 8.9428 )	-1.047 ( 41.1223 )	4.927 ( 20.9623 )	1.171 ( 10.2978 )
ALT Week 4 (41, 38, 42, 41, 41)	-3.854 ( 15.1897 )	1.553 ( 16.2758 )	-3.952 ( 38.9546 )	22.756 ( 139.8531 )	-1.561 ( 10.1392 )
ALT Week 8 (41, 39, 43, 39, 41)	-4.707 ( 13.6478 )	-1.385 ( 9.4580 )	5.465 ( 68.0764 )	0.795 ( 11.4321 )	-1.659 ( 11.1009 )
ALT Week 12 (41, 39, 42, 38, 41)	-4.220 ( 15.1765 )	0.359 ( 12.2356 )	-4.429 ( 38.1756 )	1.184 ( 13.0692 )	-1.390 ( 8.1941 )
ALT Week 16 (42, 38, 42, 38, 41)	-2.048 ( 18.0026 )	2.684 ( 16.3229 )	-4.857 ( 38.6211 )	0.579 ( 12.9273 )	0.829 ( 11.5432 )
ALT Week 20 (40, 39, 42, 37, 40)	0.300 ( 39.9482 )	3.821 ( 13.0139 )	-4.881 ( 39.1808 )	-0.838 ( 11.1118 )	-1.350 ( 10.5479 )
ALT Week 24 (39, 38, 41, 36, 40)	-1.564 ( 19.4974 )	2.789 ( 14.5475 )	-5.659 ( 39.6652 )	1.528 ( 11.0259 )	-3.475 ( 8.6202 )
ALT Week 28 (39, 38, 41, 35, 40)	-3.385 ( 17.7373 )	2.658 ( 12.8174 )	-3.244 ( 43.4688 )	-0.171 ( 8.7228 )	-2.775 ( 10.4280 )
ALT Week 32 (39, 39, 40, 34, 39)	-4.487 ( 16.5400 )	2.385 ( 12.8956 )	-4.150 ( 44.0126 )	-2.176 ( 12.7742 )	-0.821 ( 11.5482 )
ALT Week 36 (38, 38, 41, 34, 39)	0.579 ( 10.5411 )	0.184 ( 11.8660 )	-2.976 ( 42.9275 )	-0.471 ( 11.2848 )	-1.103 ( 10.6296 )
ALT Week 40 (37, 38, 41, 34, 38)	-0.622 ( 10.2506 )	0.816 ( 12.6680 )	-2.780 ( 44.9719 )	-3.853 ( 11.1059 )	-1.385 ( 13.1061 )
ALT Week 44 (37, 38, 41, 34, 36)	2.649 ( 19.7993 )	1.474 ( 13.1514 )	-3.415 ( 43.2966 )	-3.882 ( 12.8741 )	-2.692 ( 10.2525 )
ALT Week 48 (38, 37, 41, 34, 40)	2.605 ( 14.0646 )	2.216 ( 12.8542 )	-4.561 ( 43.1926 )	-3.794 ( 13.1628 )	-0.575 ( 9.6181 )
ALP Week 1 (41, 38, 43, 41, 40)	-1.098 ( 6.0034 )	-1.342 ( 8.0983 )	-2.721 ( 7.2056 )	-3.244 ( 4.9989 )	-4.275 ( 7.1360 )
ALP Week 2 (42, 39, 43, 41, 41)	-1.905 ( 6.7960 )	-3.282 ( 7.8370 )	-4.349 ( 9.5963 )	-4.805 ( 7.8237 )	-3.585 ( 8.8430 )
ALP Week 4 (41, 39, 42, 41, 41)	-1.634 ( 9.0630 )	-1.077 ( 10.4236 )	-3.262 ( 9.9144 )	-1.439 ( 18.3508 )	-4.829 ( 10.9268 )
ALP Week 8 (41, 39, 43, 39, 41)	-2.220 ( 8.3711 )	0.308 ( 12.6515 )	1.233 ( 37.8014 )	-5.026 ( 10.2019 )	-3.585 ( 9.8336 )
ALP Week 12 (41, 39, 42, 38, 41)	-2.463 ( 8.8122 )	-0.462 ( 12.1066 )	-5.952 ( 11.0695 )	-4.947 ( 12.0538 )	-3.146 ( 17.2476 )
ALP Week 16 (42, 38, 42, 38, 41)	-8.357 ( 12.7276 )	-0.895 ( 13.1515 )	-7.238 ( 10.7722 )	-4.605 ( 11.6539 )	-1.512 ( 25.7722 )
ALP Week 20 (40, 39, 42, 37, 40)	-10.425 ( 14.0510 )	-5.410 ( 15.1895 )	-10.143 ( 13.0264 )	-7.027 ( 11.8544 )	-6.650 ( 14.8143 )
ALP Week 24 (39, 39, 41, 36, 40)	-12.795 ( 15.4752 )	-4.769 ( 13.8097 )	-9.463 ( 11.3448 )	-6.361 ( 12.7843 )	-7.225 ( 18.4231 )
ALP Week 28 (39, 38, 41, 35, 40)	-12.795 ( 16.9351 )	-5.684 ( 15.7259 )	-11.244 ( 12.6249 )	-8.314 ( 10.9054 )	-8.525 ( 16.8523 )
ALP Week 32 (39, 39, 41, 35, 40)	-13.667 ( 16.1870 )	-4.769 ( 16.1530 )	-10.900 ( 13.0026 )	-9.118 ( 12.5765 )	-8.385 ( 17.5988 )
ALP Week 36 (38, 38, 41, 34, 39)	-11.816 ( 19.2436 )	-6.368 ( 15.4735 )	-11.122 ( 12.3495 )	-8.059 ( 9.5217 )	-6.487 ( 19.2434 )
ALP Week 40 (37, 38, 41, 34, 38)	-11.000 ( 16.9706 )	-5.658 ( 15.7485 )	-11.024 ( 12.9180 )	-10.559 ( 11.6987 )	-8.175 ( 17.8884 )
ALP Week 44 (37, 38, 41, 34, 40)	-12.622 ( 17.6373 )	-6.421 ( 14.9099 )	-10.537 ( 13.5759 )	-8.647 ( 10.5483 )	-8.950 ( 18.3162 )
ALP Week 48 (38, 38, 41, 34, 40)	-12.211 ( 19.0379 )	-6.500 ( 16.5313 )	-11.049 ( 14.4827 )	-7.765 ( 12.3290 )	-7.875 ( 20.1370 )
AST Week 1 (41, 38, 43, 41, 40)	-2.854 ( 10.3212 )	1.447 ( 6.2155 )	-0.023 ( 27.5409 )	2.244 ( 6.7889 )	0.475 ( 5.2963 )
AST Week 2 (42, 39, 43, 41, 41)	-1.762 ( 10.5294 )	0.487 ( 4.0967 )	-2.233 ( 26.3266 )	3.805 ( 14.7635 )	0.780 ( 6.1746 )
AST Week 4 (41, 38, 42, 41, 41)	-3.976 ( 10.6642 )	1.289 ( 7.5584 )	-3.262 ( 25.1047 )	8.927 ( 52.0660 )	-1.195 ( 4.2791 )
AST Week 8 (41, 39, 43, 39, 41)	-3.537 ( 10.5477 )	-0.077 ( 5.8687 )	2.279 ( 34.7805 )	1.410 ( 5.5900 )	0.366 ( 6.1877 )
AST Week 12 (41, 39, 42, 38, 41)	-3.049 ( 12.2106 )	0.436 ( 5.3054 )	-2.595 ( 22.5324 )	1.053 ( 6.9006 )	1.122 ( 6.2897 )
AST Week 16 (42, 38, 42, 38, 41)	-1.048 ( 12.1313 )	2.974 ( 8.3649 )	-2.595 ( 24.3852 )	1.526 ( 6.6688 )	2.122 ( 6.1733 )
AST Week 20 (40, 39, 42, 37, 40)	6.375 ( 60.1309 )	2.821 ( 6.6367 )	-1.095 ( 25.1317 )	1.324 ( 7.1065 )	0.500 ( 4.8569 )
AST Week 24 (39, 38, 41, 36, 40)	1.718 ( 23.7940 )	2.237 ( 6.9182 )	-1.902 ( 26.1054 )	2.889 ( 6.2554 )	0.325 ( 4.3759 )
AST Week 28 (39, 38, 41, 35, 40)	-1.179 ( 13.4905 )	2.289 ( 6.9512 )	-1.805 ( 27.4583 )	2.229 ( 6.3063 )	0.175 ( 4.1255 )
AST Week 32 (39, 39, 40, 34, 39)	-1.385 ( 12.2895 )	1.949 ( 6.2826 )	-0.575 ( 28.3177 )	0.324 ( 6.2654 )	2.051 ( 4.9997 )
AST Week 36 (38, 38, 41, 34, 39)	0.711 ( 7.3113 )	1.026 ( 5.5140 )	-1.220 ( 25.5798 )	1.588 ( 6.6017 )	1.667 ( 6.0755 )
AST Week 40 (37, 38, 41, 34, 39)	0.946 ( 12.1494 )	1.316 ( 5.5269 )	0.244 ( 29.2701 )	-0.647 ( 6.0597 )	2.462 ( 8.4972 )
AST Week 44 (37, 38, 41, 34, 39)	2.838 ( 15.4641 )	2.553 ( 7.9175 )	-1.268 ( 28.4280 )	-0.588 ( 7.7190 )	1.590 ( 6.9347 )
AST Week 48 (38, 37, 41, 34, 40)	2.158 ( 9.7939 )	3.459 ( 6.3403 )	-1.927 ( 28.3182 )	0.441 ( 6.6796 )	2.900 ( 6.2339 )
GGT Week 1 (41, 38, 43, 41, 40)	0.171 ( 5.4447 )	-2.737 ( 7.0354 )	-0.535 ( 10.8745 )	0.171 ( 5.0245 )	-2.300 ( 6.2684 )
GGT Week 2 (42, 39, 43, 41, 41)	-0.190 ( 5.8736 )	-2.026 ( 7.6828 )	-4.116 ( 25.7527 )	-0.341 ( 5.2517 )	-1.268 ( 7.8773 )
GGT Week 4 (41, 39, 42, 41, 41)	-0.220 ( 7.2129 )	-2.641 ( 9.9167 )	-6.143 ( 35.5504 )	1.171 ( 17.6265 )	0.512 ( 16.3968 )
GGT Week 8 (41, 39, 43, 39, 41)	-1.829 ( 5.9745 )	-4.410 ( 11.6319 )	11.581 ( 103.8974 )	-1.795 ( 5.7454 )	-1.805 ( 9.0698 )
GGT Week 12 (41, 39, 42, 38, 41)	-0.585 ( 5.9033 )	-2.154 ( 10.7643 )	-5.762 ( 34.8767 )	-0.447 ( 8.3785 )	3.244 ( 21.8229 )
GGT Week 16 (42, 38, 42, 38, 41)	-0.357 ( 9.6445 )	-1.842 ( 13.4476 )	-4.357 ( 34.0020 )	-0.947 ( 8.1868 )	15.024 ( 77.1617 )
GGT Week 20 (40, 39, 42, 37, 40)	-0.750 ( 9.5051 )	-2.769 ( 13.0555 )	-5.452 ( 32.1970 )	-1.649 ( 5.5137 )	1.475 ( 22.2722 )
GGT Week 24 (39, 39, 41, 36, 40)	-0.615 ( 12.4173 )	-2.769 ( 10.9339 )	-4.122 ( 36.6832 )	-2.639 ( 9.4360 )	-2.625 ( 10.3272 )
GGT Week 28 (39, 38, 41, 35, 40)	-0.462 ( 11.5618 )	-2.132 ( 11.7638 )	-6.341 ( 36.7434 )	-2.629 ( 7.6354 )	-0.200 ( 11.5585 )
GGT Week 32 (39, 39, 40, 34, 39)	0.359 ( 15.7872 )	-1.538 ( 13.2463 )	-7.875 ( 36.9103 )	-3.676 ( 8.6435 )	2.795 ( 21.1501 )
GGT Week 36 (38, 38, 41, 34, 39)	-0.026 ( 14.7162 )	-4.289 ( 11.4559 )	-8.195 ( 38.6899 )	-2.735 ( 7.1236 )	1.410 ( 18.0200 )
GGT Week 40 (37, 38, 41, 34, 40)	-2.568 ( 9.3676 )	-3.842 ( 13.9275 )	-9.073 ( 40.5792 )	-4.088 ( 7.5573 )	0.925 ( 20.1066 )
GGT Week 44 (37, 38, 41, 34, 39)	1.081 ( 23.2108 )	-1.289 ( 21.3730 )	-7.488 ( 34.4145 )	-3.824 ( 7.0430 )	-0.949 ( 11.5643 )
GGT Week 48 (38, 38, 41, 34, 40)	1.474 ( 17.6723 )	-2.184 ( 12.0850 )	-7.805 ( 35.4924 )	-2.941 ( 8.8247 )	2.525 ( 20.6112 )
LDH Week 1 (41, 38, 43, 41, 40)	-7.000 ( 16.1509 )	0.026 ( 19.6118 )	-1.163 ( 33.1669 )	-0.585 ( 16.6673 )	-1.075 ( 18.4341 )
LDH Week 2 (42, 39, 43, 41, 41)	-5.929 ( 18.4858 )	-0.410 ( 14.9045 )	-5.930 ( 32.8325 )	-2.439 ( 19.2146 )	0.537 ( 19.7270 )
LDH Week 4 (41, 39, 42, 41, 41)	-5.634 ( 25.5693 )	4.846 ( 21.4372 )	-6.190 ( 29.5265 )	0.854 ( 26.6238 )	-4.293 ( 17.4732 )
LDH Week 8 (41, 39, 43, 39, 41)	-3.561 ( 17.3249 )	0.026 ( 19.0449 )	0.140 ( 38.8413 )	3.513 ( 18.6503 )	1.439 ( 24.0230 )
LDH Week 12 (41, 39, 42, 38, 41)	-0.927 ( 28.3058 )	4.077 ( 21.0905 )	2.119 ( 27.5134 )	3.342 ( 17.0346 )	1.049 ( 22.9303 )
LDH Week 16 (42, 38, 42, 38, 41)	0.881 ( 26.0180 )	15.447 ( 62.0267 )	-4.381 ( 35.9600 )	0.474 ( 19.8967 )	1.488 ( 21.8325 )
LDH Week 20 (40, 39, 42, 37, 40)	1.200 ( 35.1817 )	2.154 ( 22.8825 )	2.500 ( 31.6145 )	0.676 ( 20.9206 )	2.025 ( 23.0401 )
LDH Week 24 (39, 39, 41, 36, 40)	4.462 ( 31.9282 )	1.333 ( 22.1862 )	2.878 ( 44.9662 )	1.944 ( 23.5638 )	8.550 ( 25.3093 )
LDH Week 28 (39, 38, 41, 35, 40)	1.436 ( 21.1122 )	-4.763 ( 21.2138 )	-2.902 ( 34.3590 )	8.143 ( 44.0929 )	1.250 ( 22.0962 )
LDH Week 32 (39, 39, 40, 34, 39)	-6.333 ( 23.0587 )	-6.410 ( 23.8324 )	-4.525 ( 35.2762 )	-2.971 ( 27.9171 )	-1.615 ( 24.8052 )
LDH Week 36 (38, 38, 41, 34, 39)	0.553 ( 37.3889 )	-4.658 ( 16.8383 )	-7.585 ( 35.0442 )	-6.147 ( 21.6895 )	5.436 ( 30.0436 )
LDH Week 40 (37, 38, 41, 34, 40)	-0.216 ( 34.5214 )	-8.289 ( 17.4896 )	-6.366 ( 36.6898 )	-10.618 ( 24.4293 )	0.000 ( 29.3852 )
LDH Week 44 (37, 38, 41, 34, 40)	-0.757 ( 32.2847 )	-5.316 ( 21.4805 )	-5.000 ( 34.6259 )	-5.059 ( 22.2683 )	1.675 ( 24.9588 )
LDH Week 48 (38, 38, 41, 34, 40)	4.447 ( 34.3493 )	-1.395 ( 23.8061 )	-4.707 ( 38.6654 )	-7.441 ( 23.0443 )	4.500 ( 37.8120 )

No statistical analyses for this end point

Secondary: Changes from Baseline in biochemistry parameters during the study (albumin)

Top of page

End point title

Changes from Baseline in biochemistry parameters during the study (albumin)

End point description

Albumin was measured in grams per liter (g/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: g/L
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-1.000 ( 1.7464 )	-0.079 ( 2.1357 )	0.279 ( 1.8038 )	-0.439 ( 1.8715 )	-0.350 ( 1.6259 )
Week 2 (42, 39, 43, 41, 41)	-0.500 ( 2.0982 )	0.051 ( 1.5719 )	0.419 ( 1.9908 )	-0.537 ( 2.0988 )	-0.073 ( 1.8220 )
Week 4 (41, 39, 42, 41, 41)	-0.683 ( 2.4743 )	0.538 ( 2.1007 )	0.595 ( 1.9514 )	-0.171 ( 1.9862 )	0.220 ( 1.9687 )
Week 8 (41, 39, 43, 39, 41)	-0.634 ( 2.0094 )	0.154 ( 2.1829 )	0.581 ( 2.0843 )	0.077 ( 2.2051 )	0.195 ( 1.7638 )
Week 12 (41, 39, 42, 38, 41)	0.073 ( 2.4020 )	0.538 ( 2.1986 )	0.857 ( 1.8685 )	0.211 ( 1.9474 )	0.415 ( 2.1210 )
Week 16 (42, 38, 42, 38, 41)	0.833 ( 1.8468 )	1.132 ( 2.2800 )	0.881 ( 2.0025 )	0.316 ( 2.0678 )	0.683 ( 1.9422 )
Week 20 (40, 39, 42, 37, 40)	0.175 ( 1.9333 )	0.487 ( 2.4047 )	0.976 ( 1.7873 )	-0.081 ( 2.1000 )	0.575 ( 1.8659 )
Week 24 (39, 39, 41, 36, 40)	0.385 ( 1.7262 )	0.949 ( 2.3164 )	1.341 ( 1.8790 )	0.722 ( 2.2502 )	0.875 ( 2.3004 )
Week 28 (39, 38, 41, 35, 40)	-0.462 ( 2.0881 )	0.632 ( 2.1362 )	0.976 ( 1.9169 )	0.114 ( 1.9819 )	0.525 ( 2.0999 )
Week 32 (39, 39, 40, 34, 39)	-0.179 ( 1.7452 )	0.359 ( 1.8706 )	0.700 ( 1.9897 )	-0.235 ( 1.6341 )	0.667 ( 1.9912 )
Week 36 (38, 38, 41, 34, 39)	-0.289 ( 2.6397 )	0.816 ( 1.7220 )	0.659 ( 1.6064 )	-0.029 ( 2.0815 )	0.436 ( 1.9166 )
Week 40 (37, 38, 41, 34, 40)	-0.108 ( 2.0109 )	0.763 ( 1.9650 )	0.805 ( 1.8196 )	0.000 ( 1.8749 )	0.400 ( 1.9716 )
Week 44 (37, 38, 41, 34, 40)	-0.297 ( 2.0120 )	0.132 ( 2.3269 )	0.659 ( 2.2429 )	-0.206 ( 1.9661 )	0.175 ( 2.2858 )
Week 48 (38, 38, 41, 34, 40)	0.132 ( 2.2800 )	0.632 ( 2.9903 )	0.366 ( 3.1682 )	0.088 ( 2.6671 )	0.150 ( 2.3044 )

No statistical analyses for this end point

Secondary: Changes from Baseline in biochemistry parameters during the study (bilirubin, creatinine, urate)

Top of page

End point title

Changes from Baseline in biochemistry parameters during the study (bilirubin, creatinine, urate)

End point description

Bilirubin, creatinine, urate were measured in micromols per liter (μmol/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: μmol/L
arithmetic mean (standard deviation)
Bilirubin Week 1 (41, 38, 43, 41, 40)	-0.841 ( 2.8968 )	-1.195 ( 3.1083 )	-0.465 ( 3.4868 )	0.471 ( 3.0332 )	0.385 ( 2.2726 )
Bilirubin Week 2 (42, 39, 43, 41, 41)	-0.762 ( 2.9415 )	0.492 ( 3.1202 )	0.516 ( 2.7030 )	0.978 ( 2.9538 )	1.395 ( 4.0672 )
Bilirubin Week 4 (41, 38, 42, 41, 41)	-0.290 ( 3.4900 )	0.789 ( 2.8952 )	-0.119 ( 3.2318 )	1.066 ( 3.4454 )	1.344 ( 3.7625 )
Bilirubin Week 8 (41, 39, 43, 39, 41)	-0.776 ( 3.7242 )	0.541 ( 3.1822 )	0.442 ( 3.8005 )	0.972 ( 3.4557 )	0.639 ( 2.8243 )
Bilirubin Week 12 (41, 39, 42, 38, 41)	-0.261 ( 2.6113 )	0.341 ( 3.0050 )	0.095 ( 2.5793 )	0.629 ( 3.2367 )	2.073 ( 4.0034 )
Bilirubin Week 16 (42, 38, 42, 38, 41)	0.607 ( 3.7361 )	0.637 ( 3.7786 )	0.740 ( 3.2505 )	1.092 ( 3.7662 )	2.024 ( 3.7217 )
Bilirubin Week 20 (40, 39, 42, 37, 40)	-0.007 ( 3.3543 )	0.136 ( 3.4239 )	1.062 ( 3.8164 )	1.030 ( 3.8636 )	1.225 ( 2.9632 )
Bilirubin Week 24 (39, 38, 41, 36, 40)	0.146 ( 3.2508 )	0.592 ( 4.4981 )	0.383 ( 3.1235 )	1.081 ( 2.8708 )	1.128 ( 2.8112 )
Bilirubin Week 28 (39, 38, 41, 35, 40)	-0.200 ( 3.6974 )	-0.068 ( 3.8885 )	0.105 ( 2.5550 )	0.449 ( 3.4106 )	1.595 ( 3.4093 )
Bilirubin Week 32 (39, 39, 40, 34, 39)	0.233 ( 3.2668 )	0.262 ( 3.7358 )	0.655 ( 3.1125 )	0.994 ( 2.6879 )	1.669 ( 4.0868 )
Bilirubin Week 36 (38, 38, 41, 34, 39)	0.942 ( 3.6870 )	0.776 ( 4.3703 )	0.078 ( 3.8443 )	1.012 ( 3.5311 )	1.095 ( 2.3971 )
Bilirubin Week 40 (37, 38, 41, 34, 39)	0.600 ( 3.8064 )	0.679 ( 3.4707 )	0.415 ( 3.3481 )	1.065 ( 3.1718 )	1.433 ( 3.3425 )
Bilirubin Week 44 (37, 38, 41, 34, 39)	-0.019 ( 3.6800 )	-0.276 ( 3.1827 )	-0.102 ( 3.1253 )	0.871 ( 2.8347 )	1.851 ( 3.7976 )
Bilirubin Week 48 (38, 37, 41, 34, 40)	0.716 ( 4.0370 )	0.559 ( 3.2460 )	0.285 ( 3.8393 )	1.124 ( 3.2882 )	1.160 ( 3.9493 )
Creatinine Week 1 (41, 38, 43, 41, 40)	-0.512 ( 6.6788 )	0.368 ( 7.3757 )	2.442 ( 7.8628 )	1.366 ( 8.9044 )	1.300 ( 6.7300 )
Creatinine Week 2 (42, 39, 43, 41, 41)	2.310 ( 11.1300 )	0.026 ( 6.1194 )	2.093 ( 8.4426 )	2.537 ( 6.8304 )	3.317 ( 6.7470 )
Creatinine Week 4 (41, 39, 42, 41, 41)	0.854 ( 10.2508 )	1.256 ( 7.0812 )	1.762 ( 8.8229 )	-0.561 ( 7.3418 )	2.171 ( 6.9279 )
Creatinine Week 8 (41, 39, 43, 39, 41)	1.366 ( 8.3269 )	1.487 ( 8.3756 )	3.674 ( 10.1997 )	1.590 ( 7.9131 )	3.073 ( 5.7810 )
Creatinine Week 12 (41, 39, 42, 38, 41)	1.268 ( 8.0282 )	0.949 ( 8.6113 )	6.214 ( 9.5062 )	1.947 ( 9.1236 )	2.220 ( 8.2417 )
Creatinine Week 16 (42, 38, 42, 38, 41)	1.833 ( 8.4678 )	1.421 ( 10.7945 )	3.738 ( 7.7964 )	0.658 ( 8.7897 )	3.976 ( 8.2719 )
Creatinine Week 20 (40, 39, 42, 37, 40)	3.150 ( 8.3468 )	1.051 ( 7.7966 )	4.976 ( 10.5818 )	2.270 ( 8.5461 )	4.525 ( 7.4144 )
Creatinine Week 24 (39, 39, 41, 36, 40)	1.359 ( 8.1741 )	0.103 ( 6.8817 )	3.829 ( 11.4256 )	1.972 ( 9.3914 )	4.650 ( 7.2627 )
Creatinine Week 28 (38, 38, 41, 35, 40)	2.921 ( 7.0227 )	1.737 ( 7.4858 )	4.634 ( 8.9576 )	1.371 ( 8.3634 )	4.900 ( 7.2388 )
Creatinine Week 32 (39, 39, 40, 34, 39)	1.718 ( 8.8227 )	2.462 ( 9.1360 )	2.500 ( 8.9299 )	4.118 ( 12.0825 )	4.974 ( 7.7408 )
Creatinine Week 36 (38, 38, 41, 34, 39)	0.289 ( 7.5656 )	1.632 ( 7.1600 )	1.024 ( 8.8218 )	1.853 ( 10.8492 )	3.462 ( 6.8127 )
Creatinine Week 40 (37, 38, 41, 34, 40)	3.838 ( 9.5205 )	2.974 ( 7.3796 )	4.122 ( 9.7575 )	0.647 ( 10.7672 )	3.200 ( 7.0208 )
Creatinine Week 44 (35, 36, 41, 33, 40)	4.543 ( 10.6670 )	4.250 ( 8.7876 )	3.659 ( 8.5311 )	3.364 ( 10.6853 )	3.925 ( 8.0012 )
Creatinine Week 48 (35, 33, 39, 33, 39)	3.000 ( 10.3299 )	4.667 ( 8.5355 )	3.923 ( 7.7371 )	2.879 ( 9.8513 )	3.256 ( 7.0290 )
Urate Week 1 (41, 38, 43, 41, 40)	-1.220 ( 37.4503 )	-0.237 ( 43.0100 )	11.953 ( 60.5652 )	8.732 ( 39.4088 )	11.650 ( 61.0924 )
Urate Week 2 (42, 39, 43, 41, 41)	12.405 ( 47.5795 )	-2.974 ( 44.8826 )	9.791 ( 61.4009 )	9.073 ( 39.3430 )	15.610 ( 49.0693 )
Urate Week 4 (41, 39, 42, 41, 41)	10.171 ( 41.5493 )	0.308 ( 47.3193 )	13.452 ( 49.1633 )	5.659 ( 31.2591 )	-4.293 ( 47.5753 )
Urate Week 8 (41, 39, 43, 39, 41)	5.415 ( 42.9500 )	-6.231 ( 40.4198 )	11.791 ( 64.9910 )	3.410 ( 33.9518 )	8.024 ( 44.0043 )
Urate Week 12 (41, 39, 42, 38, 41)	10.707 ( 40.2208 )	6.795 ( 54.4814 )	13.881 ( 55.3332 )	7.553 ( 33.4904 )	2.805 ( 37.6651 )
Urate Week 16 (42, 38, 42, 38, 41)	25.810 ( 44.1965 )	8.079 ( 50.0062 )	15.357 ( 59.0311 )	14.026 ( 40.5173 )	21.683 ( 41.1670 )
Urate Week 20 (40, 39, 42, 37, 40)	28.950 ( 53.8602 )	4.692 ( 59.0420 )	16.048 ( 63.4346 )	10.622 ( 42.1567 )	10.600 ( 44.3262 )
Urate Week 24 (39, 39, 41, 36, 40)	17.410 ( 45.0045 )	9.923 ( 54.9648 )	3.683 ( 58.6977 )	6.667 ( 45.2580 )	6.950 ( 45.8638 )
Urate Week 28 (39, 38, 41, 35, 40)	-0.897 ( 29.4331 )	9.447 ( 59.8655 )	18.976 ( 62.4894 )	-6.371 ( 40.1227 )	1.250 ( 45.8972 )
Urate Week 32 (39, 39, 40, 34, 39)	17.026 ( 47.8185 )	2.821 ( 48.9042 )	5.800 ( 56.2017 )	3.971 ( 45.1103 )	17.077 ( 40.3089 )
Urate Week 36 (38, 38, 41, 34, 39)	0.211 ( 37.5630 )	-4.868 ( 49.1419 )	-10.927 ( 59.4228 )	4.735 ( 42.4309 )	5.846 ( 49.4259 )
Urate Week 40 (37, 38, 41, 34, 40)	9.730 ( 43.5295 )	15.605 ( 53.8931 )	9.976 ( 62.8739 )	-5.029 ( 41.2630 )	7.255 ( 46.0833 )
Urate Week 44 (37, 38, 41, 34, 40)	20.541 ( 57.9164 )	7.605 ( 64.3342 )	-8.854 ( 67.3523 )	1.382 ( 47.9558 )	10.675 ( 50.8963 )
Urate Week 48 (38, 38, 41, 34, 40)	8.684 ( 53.6208 )	3.895 ( 48.5831 )	-3.220 ( 64.9282 )	1.853 ( 54.8762 )	8.050 ( 49.1956 )

No statistical analyses for this end point

Secondary: Changes from Baseline in biochemistry parameters during the study (calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium)

Top of page

End point title

Changes from Baseline in biochemistry parameters during the study (calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium)

End point description

Calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium were measured in millimoles per liter (mmol/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: mmol/L
arithmetic mean (standard deviation)
Calcium Week 1 (41, 38, 43, 41, 40)	-0.034 ( 0.0810 )	-0.017 ( 0.0984 )	-0.008 ( 0.0858 )	-0.002 ( 0.0990 )	-0.014 ( 0.0897 )
Calcium Week 2 (42, 39, 43, 41, 41)	-0.021 ( 0.0951 )	0.002 ( 0.0973 )	0.009 ( 0.1304 )	-0.024 ( 0.1001 )	-0.022 ( 0.0938 )
Calcium Week 4 (41, 39, 42, 41, 41)	-0.029 ( 0.1079 )	-0.011 ( 0.1015 )	-0.021 ( 0.0973 )	-0.047 ( 0.1147 )	-0.020 ( 0.0917 )
Calcium Week 8 (41, 39, 43, 39, 41)	-0.024 ( 0.0942 )	-0.006 ( 0.0926 )	0.008 ( 0.1260 )	-0.004 ( 0.1105 )	-0.022 ( 0.0975 )
Calcium Week 12 (41, 39, 42, 38, 41)	-0.021 ( 0.1009 )	-0.025 ( 0.1090 )	0.021 ( 0.1057 )	-0.020 ( 0.1088 )	-0.025 ( 0.0923 )
Calcium Week 16 (42, 38, 42, 38, 41)	0.004 ( 0.0826 )	-0.006 ( 0.1079 )	0.023 ( 0.1334 )	-0.004 ( 0.1027 )	0.005 ( 0.0888 )
Calcium Week 20 (40, 39, 42, 37, 40)	0.002 ( 0.0931 )	0.000 ( 0.1013 )	0.017 ( 0.0999 )	-0.008 ( 0.0948 )	-0.018 ( 0.0919 )
Calcium Week 24 (39, 39, 41, 36, 40)	0.011 ( 0.1019 )	-0.002 ( 0.1028 )	0.015 ( 0.0845 )	0.004 ( 0.0896 )	0.003 ( 0.0974 )
Calcium Week 28 (39, 38, 41, 35, 40)	-0.027 ( 0.1117 )	0.002 ( 0.0877 )	0.009 ( 0.1068 )	0.008 ( 0.0909 )	-0.021 ( 0.1043 )
Calcium Week 32 (39, 39, 40, 34, 39)	-0.023 ( 0.1069 )	0.000 ( 0.0952 )	0.001 ( 0.1074 )	-0.017 ( 0.0932 )	-0.008 ( 0.1024 )
Calcium Week 36 (38, 38, 41, 34, 39)	-0.013 ( 0.1172 )	0.007 ( 0.0804 )	-0.005 ( 0.1096 )	0.001 ( 0.0972 )	-0.015 ( 0.0936 )
Calcium Week 40 (37, 38, 41, 34, 40)	0.003 ( 0.0905 )	0.001 ( 0.0807 )	-0.007 ( 0.1084 )	-0.019 ( 0.0809 )	-0.025 ( 0.0947 )
Calcium Week 44 (37, 38, 41, 34, 40)	-0.027 ( 0.0920 )	-0.018 ( 0.0861 )	-0.008 ( 0.1023 )	-0.019 ( 0.0839 )	-0.042 ( 0.0972 )
Calcium Week 48 (38, 38, 41, 34, 40)	-0.010 ( 0.0881 )	-0.009 ( 0.1033 )	-0.014 ( 0.1126 )	-0.014 ( 0.0912 )	-0.034 ( 0.0861 )
Chloride Week 1 (41, 38, 43, 41, 40)	-0.195 ( 2.1121 )	-0.105 ( 2.5446 )	-0.674 ( 4.1388 )	-0.244 ( 2.5572 )	-0.125 ( 2.3986 )
Chloride Week 2 (42, 39, 43, 41, 41)	-0.214 ( 2.1131 )	0.308 ( 2.6273 )	0.093 ( 2.7500 )	0.415 ( 2.5296 )	-0.439 ( 2.4192 )
Chloride Week 4 (41, 39, 42, 41, 41)	-0.293 ( 1.9525 )	-0.333 ( 2.2750 )	0.000 ( 2.4792 )	0.024 ( 2.6409 )	0.000 ( 2.6363 )
Chloride Week 8 (41, 39, 43, 39, 41)	-0.537 ( 2.1920 )	0.615 ( 2.4346 )	0.047 ( 2.6988 )	0.538 ( 2.3038 )	0.683 ( 2.4025 )
Chloride Week 12 (41, 39, 42, 38, 41)	0.341 ( 2.2205 )	-0.282 ( 2.3946 )	0.548 ( 2.5681 )	-0.211 ( 2.3499 )	0.000 ( 2.4393 )
Chloride Week 16 (42, 38, 42, 38, 41)	-0.310 ( 1.8934 )	0.026 ( 2.2837 )	0.190 ( 2.0864 )	-0.184 ( 2.2644 )	-0.268 ( 2.1334 )
Chloride Week 20 (40, 39, 42, 37, 40)	-0.325 ( 2.4640 )	-0.538 ( 2.1502 )	0.262 ( 2.3484 )	0.162 ( 2.6616 )	0.075 ( 2.3685 )
Chloride Week 24 (39, 39, 41, 36, 40)	-0.615 ( 2.0081 )	-0.128 ( 2.5462 )	-0.390 ( 2.6351 )	-0.306 ( 2.1885 )	-0.050 ( 2.5415 )
Chloride Week 28 (39, 38, 41, 35, 40)	0.128 ( 2.3190 )	0.000 ( 2.6913 )	0.195 ( 2.3154 )	0.086 ( 2.5365 )	0.250 ( 2.5090 )
Chloride Week 32 (39, 39, 40, 34, 39)	-0.154 ( 2.2069 )	0.436 ( 2.3708 )	0.500 ( 2.2072 )	0.794 ( 2.3196 )	0.282 ( 2.0641 )
Chloride Week 36 (38, 38, 41, 34, 39)	0.237 ( 1.9923 )	0.684 ( 2.4285 )	0.732 ( 1.9239 )	0.294 ( 2.5999 )	0.205 ( 2.4299 )
Chloride Week 40 (37, 38, 41, 34, 40)	-0.054 ( 2.5380 )	0.263 ( 2.6271 )	0.707 ( 2.4418 )	0.824 ( 2.4676 )	0.500 ( 2.4495 )
Chloride Week 44 (37, 38, 41, 34, 40)	0.135 ( 1.9027 )	0.579 ( 2.6977 )	0.756 ( 2.1069 )	0.882 ( 2.8044 )	0.200 ( 2.5840 )
Chloride Week 48 (38, 38, 41, 34, 40)	0.605 ( 2.0994 )	0.737 ( 2.8158 )	1.024 ( 2.4545 )	0.971 ( 2.5044 )	0.725 ( 2.7826 )
Cholesterol Week 1 (41, 38, 43, 41, 40)	-0.254 ( 0.4371 )	0.032 ( 0.4307 )	0.244 ( 0.5220 )	0.105 ( 0.4690 )	0.102 ( 0.3965 )
Cholesterol Week 2 (42, 39, 43, 41, 41)	-0.224 ( 0.4154 )	0.108 ( 0.5132 )	0.295 ( 0.5178 )	0.054 ( 0.5441 )	0.222 ( 0.6101 )
Cholesterol Week 4 (41, 39, 42, 41, 41)	-0.198 ( 0.6334 )	-0.023 ( 0.5905 )	0.210 ( 0.8027 )	0.093 ( 0.6525 )	0.151 ( 0.4178 )
Cholesterol Week 8 (41, 39, 43, 39, 41)	-0.190 ( 0.6935 )	-0.023 ( 0.5770 )	0.284 ( 0.8012 )	0.074 ( 0.7920 )	0.061 ( 0.6268 )
Cholesterol Week 12 (41, 39, 42, 38, 41)	-0.124 ( 0.6719 )	0.013 ( 0.7473 )	0.117 ( 0.7616 )	0.005 ( 0.6045 )	0.212 ( 0.7491 )
Cholesterol Week 16 (42, 38, 42, 38, 41)	0.095 ( 0.6811 )	0.184 ( 0.6378 )	0.138 ( 0.6814 )	0.068 ( 0.6014 )	0.249 ( 0.7075 )
Cholesterol Week 20 (40, 39, 42, 37, 40)	0.053 ( 0.7609 )	0.126 ( 0.6889 )	0.186 ( 0.9669 )	0.116 ( 0.7101 )	0.115 ( 0.7718 )
Cholesterol Week 24 (39, 39, 41, 36, 40)	0.041 ( 0.8729 )	0.013 ( 0.8673 )	0.127 ( 1.0682 )	-0.003 ( 0.6984 )	0.077 ( 0.5686 )
Cholesterol Week 28 (39, 38, 41, 35, 40)	-0.044 ( 0.9797 )	-0.037 ( 0.8930 )	0.076 ( 1.1434 )	-0.037 ( 0.5801 )	0.100 ( 0.5923 )
Cholesterol Week 32 (39, 39, 40, 34, 39)	-0.085 ( 0.8540 )	-0.079 ( 0.8918 )	0.175 ( 1.0895 )	-0.050 ( 0.5945 )	0.256 ( 0.6920 )
Cholesterol Week 36 (38, 38, 41, 34, 39)	0.005 ( 0.7322 )	0.024 ( 0.7951 )	0.117 ( 0.8408 )	-0.038 ( 0.6597 )	0.144 ( 0.7950 )
Cholesterol Week 40 (37, 38, 41, 34, 40)	-0.103 ( 0.7541 )	-0.118 ( 0.9109 )	0.183 ( 0.8947 )	-0.135 ( 0.7454 )	0.110 ( 0.7824 )
Cholesterol Week 44 (37, 38, 41, 34, 39)	-0.170 ( 0.8082 )	-0.176 ( 1.0874 )	0.071 ( 0.9341 )	-0.218 ( 0.9150 )	-0.000 ( 0.8407 )
Cholesterol Week 48 (38, 38, 41, 34, 40)	-0.282 ( 0.7891 )	-0.279 ( 0.8348 )	0.012 ( 0.8883 )	-0.253 ( 0.6653 )	-0.083 ( 0.5817 )
Glucose Week 1 (41, 38, 43, 41, 40)	0.307 ( 1.3942 )	0.103 ( 0.7027 )	0.077 ( 1.1366 )	0.173 ( 1.0232 )	-0.060 ( 0.8445 )
Glucose Week 2 (42, 39, 43, 41, 41)	0.062 ( 0.6681 )	0.013 ( 0.8348 )	0.221 ( 0.9652 )	0.129 ( 1.2364 )	0.190 ( 0.8938 )
Glucose Week 4 (41, 39, 42, 41, 41)	0.298 ( 0.8575 )	0.015 ( 0.6888 )	0.248 ( 0.7693 )	0.249 ( 1.0659 )	0.134 ( 0.7428 )
Glucose Week 8 (41, 39, 43, 39, 41)	0.112 ( 0.9127 )	0.308 ( 0.7696 )	0.258 ( 0.9254 )	0.344 ( 0.6939 )	0.256 ( 0.7075 )
Glucose Week 12 (41, 39, 42, 38, 41)	0.110 ( 0.9146 )	0.005 ( 0.6117 )	0.188 ( 0.7533 )	0.111 ( 0.6455 )	-0.124 ( 0.6636 )
Glucose Week 16 (42, 37, 42, 38, 41)	0.176 ( 0.8363 )	0.195 ( 0.6316 )	0.424 ( 1.1521 )	0.276 ( 0.8280 )	0.398 ( 0.8332 )
Glucose Week 20 (40, 39, 42, 37, 40)	0.208 ( 1.0560 )	0.315 ( 1.0225 )	0.267 ( 1.0132 )	0.632 ( 0.9741 )	0.165 ( 1.0366 )
Glucose Week 24 (39, 39, 40, 36, 40)	0.018 ( 1.1856 )	0.092 ( 0.7747 )	0.328 ( 0.8554 )	0.061 ( 1.0462 )	0.037 ( 0.6295 )
Glucose Week 28 (39, 38, 41, 35, 40)	0.246 ( 1.1812 )	0.263 ( 0.9371 )	0.322 ( 1.1372 )	0.263 ( 1.0053 )	0.262 ( 0.6412 )
Glucose Week 32 (39, 39, 40, 34, 39)	0.333 ( 1.2671 )	0.236 ( 0.7013 )	0.570 ( 1.0301 )	0.356 ( 1.1021 )	0.203 ( 0.5945 )
Glucose Week 36 (38, 38, 41, 34, 39)	0.089 ( 0.9061 )	0.342 ( 0.9406 )	0.234 ( 1.0379 )	0.174 ( 1.0175 )	0.290 ( 0.7789 )
Glucose Week 40 (37, 38, 41, 34, 40)	0.143 ( 1.0885 )	0.245 ( 1.1081 )	0.507 ( 1.1257 )	0.203 ( 0.7420 )	0.125 ( 0.7016 )
Glucose Week 44 (37, 38, 41, 34, 39)	0.222 ( 1.4919 )	0.200 ( 1.0950 )	0.185 ( 0.8688 )	0.303 ( 1.2760 )	0.197 ( 0.8966 )
Glucose Week 48 (38, 38, 41, 34, 40)	-0.013 ( 1.2512 )	0.045 ( 0.8472 )	0.141 ( 0.9341 )	0.276 ( 1.0841 )	0.100 ( 0.7835 )
Magnesium Week 1 (41, 38, 43, 41, 40)	-0.010 ( 0.0672 )	-0.007 ( 0.0676 )	0.002 ( 0.0694 )	-0.014 ( 0.0573 )	-0.015 ( 0.0680 )
Magnesium Week 2 (42, 39, 43, 41, 41)	-0.004 ( 0.0795 )	0.008 ( 0.0745 )	-0.011 ( 0.0771 )	-0.019 ( 0.0624 )	-0.007 ( 0.0680 )
Magnesium Week 4 (41, 39, 42, 41, 41)	-0.022 ( 0.0606 )	0.009 ( 0.0725 )	-0.012 ( 0.0789 )	-0.020 ( 0.0712 )	-0.005 ( 0.0998 )
Magnesium Week 8 (41, 39, 43, 39, 41)	-0.016 ( 0.0706 )	-0.008 ( 0.0593 )	-0.013 ( 0.0819 )	-0.015 ( 0.0706 )	-0.006 ( 0.0624 )
Magnesium Week 12 (41, 39, 42, 38, 41)	0.010 ( 0.0797 )	0.008 ( 0.0847 )	-0.011 ( 0.0733 )	-0.001 ( 0.0660 )	0.003 ( 0.0730 )
Magnesium Week 16 (42, 38, 42, 38, 41)	-0.002 ( 0.0742 )	0.003 ( 0.0823 )	-0.021 ( 0.0659 )	-0.009 ( 0.0629 )	-0.002 ( 0.0731 )
Magnesium Week 20 (40, 39, 42, 37, 40)	-0.007 ( 0.0811 )	-0.012 ( 0.0728 )	-0.018 ( 0.0659 )	-0.005 ( 0.0724 )	-0.009 ( 0.0636 )
Magnesium Week 24 (39, 39, 41, 36, 40)	-0.005 ( 0.0757 )	-0.004 ( 0.0572 )	-0.014 ( 0.0732 )	-0.009 ( 0.0559 )	-0.016 ( 0.0664 )
Magnesium Week 28 (39, 38, 41, 35, 40)	-0.027 ( 0.0713 )	-0.007 ( 0.0525 )	-0.018 ( 0.0678 )	-0.019 ( 0.0719 )	-0.017 ( 0.0565 )
Magnesium Week 32 (39, 39, 40, 34, 39)	-0.023 ( 0.0727 )	-0.016 ( 0.0641 )	-0.016 ( 0.0603 )	-0.012 ( 0.0670 )	-0.013 ( 0.0572 )
Magnesium Week 36 (38, 38, 41, 34, 39)	-0.015 ( 0.0694 )	-0.001 ( 0.0596 )	-0.031 ( 0.0698 )	-0.004 ( 0.0534 )	-0.007 ( 0.0563 )
Magnesium Week 40 (37, 38, 41, 34, 40)	-0.032 ( 0.0681 )	-0.007 ( 0.0541 )	-0.014 ( 0.0754 )	-0.024 ( 0.0636 )	-0.009 ( 0.0684 )
Magnesium Week 44 (37, 38, 41, 34, 40)	-0.024 ( 0.0677 )	-0.000 ( 0.0597 )	-0.009 ( 0.0685 )	-0.024 ( 0.0668 )	-0.016 ( 0.0667 )
Magnesium Week 48 (38, 38, 41, 34, 40)	-0.004 ( 0.0633 )	-0.004 ( 0.0546 )	-0.014 ( 0.0569 )	-0.006 ( 0.0616 )	-0.009 ( 0.0648 )
Potassium Week 1 (41, 38, 43, 41, 40)	-0.095 ( 0.2701 )	0.089 ( 0.3608 )	0.081 ( 0.4289 )	-0.017 ( 0.3098 )	-0.062 ( 0.3216 )
Potassium Week 2 (42, 39, 43, 41, 41)	-0.098 ( 0.2975 )	0.085 ( 0.4095 )	0.002 ( 0.3327 )	-0.005 ( 0.3521 )	0.027 ( 0.3074 )
Potassium Week 4 (41, 39, 42, 41, 41)	-0.080 ( 0.2522 )	0.008 ( 0.3821 )	0.026 ( 0.2632 )	0.024 ( 0.4030 )	-0.063 ( 0.2853 )
Potassium Week 8 (41, 39, 43, 39, 41)	-0.056 ( 0.2907 )	0.069 ( 0.3221 )	0.014 ( 0.3306 )	-0.010 ( 0.3135 )	0.000 ( 0.2520 )
Potassium Week 12 (41, 39, 42, 38, 41)	-0.073 ( 0.3217 )	0.033 ( 0.3398 )	-0.024 ( 0.3192 )	-0.082 ( 0.3074 )	-0.080 ( 0.2977 )
Potassium Week 16 (42, 36, 42, 38, 41)	-0.086 ( 0.3258 )	0.083 ( 0.3112 )	0.012 ( 0.3651 )	-0.037 ( 0.3035 )	-0.020 ( 0.2713 )
Potassium Week 20 (40, 39, 42, 37, 40)	-0.092 ( 0.3846 )	0.031 ( 0.3381 )	0.055 ( 0.3494 )	-0.019 ( 0.3627 )	0.000 ( 0.2774 )
Potassium Week 24 (39, 39, 40, 36, 40)	-0.095 ( 0.3308 )	-0.072 ( 0.3052 )	0.030 ( 0.3844 )	-0.094 ( 0.3414 )	-0.062 ( 0.2967 )
Potassium Week 28 (39, 38, 41, 35, 40)	-0.077 ( 0.3141 )	0.105 ( 0.3616 )	0.063 ( 0.4265 )	-0.003 ( 0.3312 )	-0.030 ( 0.3480 )
Potassium Week 32 (39, 39, 40, 34, 39)	-0.062 ( 0.3306 )	0.069 ( 0.3621 )	0.023 ( 0.4154 )	0.056 ( 0.2688 )	0.046 ( 0.3094 )
Potassium Week 36 (38, 38, 41, 34, 39)	-0.092 ( 0.3388 )	0.045 ( 0.3689 )	0.066 ( 0.4316 )	0.003 ( 0.3205 )	0.033 ( 0.3359 )
Potassium Week 40 (37, 38, 41, 34, 40)	-0.092 ( 0.3616 )	0.089 ( 0.3826 )	0.024 ( 0.3484 )	-0.003 ( 0.3407 )	-0.017 ( 0.3456 )
Potassium Week 44 (37, 38, 41, 34, 40)	-0.119 ( 0.2933 )	0.029 ( 0.3571 )	0.068 ( 0.4344 )	0.094 ( 0.3084 )	-0.035 ( 0.3009 )
Potassium Week 48 (38, 38, 41, 34, 40)	-0.137 ( 0.3627 )	-0.053 ( 0.3244 )	-0.032 ( 0.3274 )	0.003 ( 0.4123 )	-0.027 ( 0.3250 )
Sodium Week 1 (41, 38, 43, 41, 40)	-0.146 ( 1.5582 )	-0.184 ( 1.7531 )	0.000 ( 2.0471 )	-0.610 ( 2.0722 )	-0.375 ( 2.1326 )
Sodium Week 2 (42, 39, 43, 41, 41)	-0.500 ( 1.6417 )	-0.513 ( 1.8191 )	-0.209 ( 1.9341 )	-0.244 ( 2.0221 )	-0.341 ( 2.1167 )
Sodium Week 4 (41, 39, 42, 41, 41)	-0.732 ( 1.8442 )	-0.385 ( 1.6482 )	-0.214 ( 2.3430 )	-0.707 ( 2.0155 )	-0.805 ( 1.8196 )
Sodium Week 8 (41, 39, 43, 39, 41)	-0.854 ( 2.0070 )	-0.410 ( 1.3711 )	-0.860 ( 2.2316 )	-0.359 ( 1.7394 )	-0.463 ( 2.2924 )
Sodium Week 12 (41, 39, 42, 38, 41)	-0.512 ( 1.8858 )	-0.513 ( 1.4845 )	-0.619 ( 2.0357 )	-0.632 ( 2.1738 )	-0.854 ( 2.3512 )
Sodium Week 16 (42, 38, 42, 38, 41)	-0.738 ( 1.8086 )	-0.211 ( 1.7423 )	-0.714 ( 1.7708 )	-0.842 ( 2.3656 )	-0.780 ( 1.7250 )
Sodium Week 20 (40, 39, 42, 37, 40)	-0.675 ( 1.7155 )	-0.538 ( 1.4482 )	-0.857 ( 2.1928 )	-0.595 ( 2.1661 )	-0.775 ( 1.9147 )
Sodium Week 24 (39, 39, 41, 36, 40)	-0.821 ( 1.7751 )	-0.487 ( 1.5196 )	-0.463 ( 2.0137 )	-0.472 ( 1.8124 )	-0.725 ( 1.7393 )
Sodium Week 28 (39, 38, 41, 35, 40)	-0.462 ( 2.2924 )	-0.658 ( 1.8494 )	-0.683 ( 1.8767 )	-0.457 ( 2.3307 )	-0.575 ( 2.5609 )
Sodium Week 32 (39, 39, 40, 34, 39)	-1.077 ( 1.8692 )	-0.128 ( 1.9219 )	-0.525 ( 1.8809 )	-0.441 ( 1.6732 )	-0.667 ( 1.8257 )
Sodium Week 36 (38, 38, 41, 34, 39)	-0.711 ( 2.0122 )	-0.263 ( 1.8986 )	-0.512 ( 1.8725 )	-0.618 ( 1.9850 )	-0.436 ( 2.2337 )
Sodium Week 40 (37, 38, 41, 34, 40)	-0.432 ( 2.1153 )	-0.474 ( 1.6397 )	-0.512 ( 2.1578 )	-0.882 ( 1.9812 )	-0.950 ( 2.0248 )
Sodium Week 44 (37, 38, 41, 34, 40)	-0.486 ( 1.8352 )	-0.737 ( 2.0492 )	-0.878 ( 1.9390 )	-0.647 ( 1.8238 )	-1.000 ( 2.4179 )
Sodium Week 48 (38, 38, 41, 34, 40)	-0.237 ( 1.7772 )	-0.763 ( 1.8074 )	-0.732 ( 1.8845 )	-0.706 ( 1.5281 )	-0.750 ( 2.1334 )

No statistical analyses for this end point

Secondary: Changes from Baseline in biochemistry parameters during the study (urea nitrogen)

Top of page

End point title

Changes from Baseline in biochemistry parameters during the study (urea nitrogen)

End point description

Urea nitrogen was measured in millimoles per liter (mmol/L). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	41	38	43	41	40
Units: mmol/L
arithmetic mean (standard deviation)
Week 1 (41, 38, 43, 41, 40)	-0.093 ( 1.0815 )	0.126 ( 1.2116 )	-0.123 ( 1.0989 )	-0.012 ( 1.0900 )	0.173 ( 1.5513 )
Week 2 (42, 39, 43, 41, 41)	0.386 ( 1.8183 )	-0.208 ( 1.1329 )	-0.047 ( 1.0359 )	0.024 ( 1.1762 )	0.212 ( 1.3064 )
Week 4 (41, 39, 42, 41, 41)	0.027 ( 1.3217 )	0.013 ( 1.1307 )	0.083 ( 1.1244 )	-0.224 ( 1.1449 )	0.007 ( 1.2384 )
Week 8 (41, 39, 43, 39, 41)	0.007 ( 0.9936 )	0.023 ( 1.1685 )	-0.070 ( 1.1143 )	-0.379 ( 1.2316 )	0.080 ( 1.1265 )
Week 12 (41, 39, 42, 38, 41)	-0.166 ( 1.2654 )	-0.244 ( 1.1740 )	-0.231 ( 1.3357 )	-0.429 ( 1.1733 )	-0.151 ( 1.2426 )
Week 16 (42, 38, 42, 38, 41)	-0.133 ( 1.0656 )	-0.087 ( 0.9793 )	-0.200 ( 1.3083 )	-0.218 ( 1.0747 )	0.012 ( 1.1996 )
Week 20 (40, 39, 42, 37, 40)	-0.207 ( 1.2670 )	-0.490 ( 1.0901 )	-0.064 ( 1.2916 )	-0.357 ( 1.1572 )	-0.035 ( 1.3202 )
Week 24 (39, 39, 41, 36, 40)	-0.256 ( 1.1378 )	-0.523 ( 1.1235 )	-0.232 ( 1.4951 )	-0.289 ( 1.1369 )	-0.138 ( 1.2245 )
Week 28 (39, 38, 41, 35, 40)	-0.267 ( 1.3487 )	-0.287 ( 1.0992 )	0.012 ( 1.3020 )	-0.263 ( 1.1835 )	-0.082 ( 1.3239 )
Week 32 (39, 39, 40, 34, 39)	-0.097 ( 1.0396 )	-0.141 ( 1.3098 )	-0.200 ( 1.1266 )	-0.326 ( 1.1199 )	0.082 ( 1.1841 )
Week 36 (38, 38, 41, 34, 39)	-0.203 ( 1.0579 )	-0.308 ( 1.1757 )	0.015 ( 1.1094 )	-0.247 ( 1.1683 )	-0.018 ( 1.1014 )
Week 40 (37, 38, 41, 34, 40)	-0.214 ( 1.2537 )	0.192 ( 1.3690 )	0.068 ( 1.1230 )	-0.132 ( 1.1834 )	0.283 ( 1.3435 )
Week 44 (37, 38, 41, 34, 39)	-0.105 ( 1.3389 )	-0.047 ( 1.3456 )	-0.054 ( 1.1276 )	-0.229 ( 1.1979 )	0.210 ( 1.2264 )
Week 48 (38, 38, 41, 34, 40)	-0.111 ( 1.4431 )	-0.113 ( 1.1796 )	-0.222 ( 1.4085 )	-0.285 ( 1.2611 )	0.088 ( 1.4580 )

No statistical analyses for this end point

Secondary: Changes from Baseline in urinalysis parameters during the study (erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells)

Top of page

End point title

Changes from Baseline in urinalysis parameters during the study (erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells)

End point description

Erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells were measured in cells per high power field (cells/HPF). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Number of participants reflect those with non-missing urinalysis results during the study. Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed and for groups that had 0 participants analyzed. Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	1	4	3	5	3
Units: cells/HPF
arithmetic mean (standard deviation)
Erythrocytes Week 1 (1, 4, 3, 5, 3)	-55.000 ( 999 )	0.750 ( 0.9574 )	0.333 ( 0.5774 )	0.000 ( 0.0000 )	0.333 ( 0.5774 )
Erythrocytes Week 2 (1, 4, 4, 4, 3)	-54.000 ( 999 )	-0.500 ( 0.5774 )	0.250 ( 0.5000 )	0.000 ( 0.0000 )	1.333 ( 2.5166 )
Erythrocytes Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	3.333 ( 5.7735 )	0.000 ( 0.7071 )	0.250 ( 0.5000 )	-0.500 ( 0.7071 )
Erythrocytes Week 8 (0, 3, 4, 2, 3)	999 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.8165 )	0.000 ( 0.0000 )	0.000 ( 1.0000 )
Erythrocytes Week 12 (1, 3, 5, 2, 3)	-23.000 ( 999 )	0.000 ( 0.0000 )	0.800 ( 1.3038 )	0.000 ( 0.0000 )	-0.333 ( 0.5774 )
Erythrocytes Week 16 (1, 5, 4, 5, 2)	-55.000 ( 999 )	0.800 ( 1.7889 )	0.500 ( 1.7321 )	0.000 ( 0.0000 )	2.500 ( 3.5355 )
Erythrocytes Week 20 (2, 4, 5, 6, 4)	-30.000 ( 35.3553 )	0.000 ( 0.0000 )	0.400 ( 1.1402 )	0.000 ( 0.0000 )	0.250 ( 0.5000 )
Erythrocytes Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	-0.250 ( 0.5000 )	0.250 ( 0.5000 )	-0.143 ( 0.8997 )	1.000 ( 2.6458 )
Erythrocytes Week 28 (1, 4, 5, 4, 3)	-5.000 ( 999 )	0.000 ( 0.8165 )	0.400 ( 1.5166 )	0.000 ( 0.0000 )	2.333 ( 5.7735 )
Erythrocytes Week 32 (2, 3, 4, 6, 3)	-27.500 ( 38.8909 )	0.000 ( 0.0000 )	0.250 ( 0.5000 )	0.000 ( 0.0000 )	2.000 ( 3.4641 )
Erythrocytes Week 36 (1, 6, 4, 1, 1)	-55.000 ( 999 )	0.000 ( 0.0000 )	0.250 ( 0.5000 )	0.000 ( 999 )	-1.000 ( 999 )
Erythrocytes Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	-0.250 ( 0.5000 )	0.750 ( 1.5000 )	-0.250 ( 0.5000 )	0.000 ( 0.0000 )
Erythrocytes Week 44 (1, 5, 5, 4, 2)	-55.000 ( 999 )	0.000 ( 0.0000 )	0.400 ( 0.8944 )	-0.250 ( 1.2583 )	0.000 ( 0.0000 )
Erythrocytes Week 48 (2, 6, 4, 3, 4)	-27.500 ( 38.8909 )	0.167 ( 0.4082 )	1.750 ( 3.5000 )	0.000 ( 0.0000 )	0.000 ( 0.8165 )
Leukocytes Week 1 (1, 4, 3, 5, 3)	0.000 ( 999 )	2.750 ( 6.1847 )	-7.667 ( 13.2791 )	-0.200 ( 1.0954 )	0.667 ( 1.1547 )
Leukocytes Week 2 (1, 4, 4, 4, 3)	2.000 ( 999 )	-2.500 ( 2.0817 )	-3.000 ( 6.6833 )	-0.250 ( 0.5000 )	0.000 ( 0.0000 )
Leukocytes Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	-4.600 ( 10.2372 )	0.250 ( 0.5000 )	2.000 ( 2.8284 )
Leukocytes Week 8 (0, 2, 4, 2, 3))	999 ( 999 )	0.000 ( 0.0000 )	-1.500 ( 3.6968 )	0.000 ( 0.0000 )	4.000 ( 6.9282 )
Leukocytes Week 12 (1, 3, 4, 2, 3)	0.000 ( 999 )	1.667 ( 4.7258 )	13.500 ( 26.3376 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Leukocytes Week 16 (1, 5, 4, 5, 2)	0.000 ( 999 )	-0.200 ( 1.7889 )	33.750 ( 67.5000 )	-0.400 ( 0.8944 )	0.500 ( 0.7071 )
Leukocytes Week 20 (2, 4, 5, 6, 4)	0.000 ( 2.8284 )	3.000 ( 6.0000 )	57.800 ( 145.4036 )	0.667 ( 1.5055 )	-6.750 ( 14.8633 )
Leukocytes Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	2.750 ( 4.8563 )	-6.500 ( 13.0000 )	2.286 ( 4.8206 )	0.333 ( 0.5774 )
Leukocytes Week 28 (1, 4, 5, 4, 3)	-2.000 ( 999 )	-0.750 ( 0.9574 )	-5.400 ( 12.0748 )	0.000 ( 0.0000 )	2.333 ( 4.0415 )
Leukocytes Week 32 (2, 3, 4, 6, 3)	0.000 ( 0.0000 )	3.333 ( 5.7735 )	-6.500 ( 13.0000 )	-1.333 ( 1.6330 )	1.333 ( 2.3094 )
Leukocytes Week 36 (1, 6, 4, 1, 1)	0.000 ( 999 )	0.667 ( 2.7325 )	0.000 ( 0.0000 )	24.000 ( 999 )	0.000 ( 999 )
Leukocytes Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	-0.500 ( 2.5166 )	-7.500 ( 15.0000 )	1.500 ( 3.0000 )	0.000 ( 0.0000 )
Leukocytes Week 44 (1, 5, 5, 4, 2)	0.000 ( 999 )	0.400 ( 0.8944 )	-1.400 ( 3.1305 )	-0.500 ( 1.0000 )	0.000 ( 0.0000 )
Leukocytes Week 48 (2, 6, 4, 3, 4)	0.000 ( 0.0000 )	8.000 ( 21.6148 )	69.500 ( 139.0000 )	-1.000 ( 1.7321 )	0.250 ( 0.5000 )
Renal Casts Week 1 (1, 4, 3, 5, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 2 (1, 4, 4, 4, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 8 (0, 3, 4, 2, 3)	999 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 12 (1, 3, 5, 2, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 16 (1, 5, 4, 5, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 20 (2, 4, 5, 6, 4)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 28 (1, 4, 5, 4, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 32 (2, 3, 4, 6, 3)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 36 (1, 6, 4, 1, 1)	0.000 ( 999 )	0.167 ( 0.4082 )	0.000 ( 0.0000 )	0.000 ( 999 )	0.000 ( 999 )
Renal Casts Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 44 (1, 5, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Renal Casts Week 48 (2, 6, 4, 3, 4)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Squamous Cells Week 1 (1, 4, 3, 5, 3)	0.000 ( 999 )	0.250 ( 1.2583 )	3.000 ( 5.1962 )	-0.200 ( 0.4472 )	-0.333 ( 0.5774 )
Squamous Cells Week 2 (1, 4, 4, 4, 3)	1.000 ( 999 )	-8.000 ( 14.6969 )	-0.250 ( 3.6856 )	0.000 ( 0.0000 )	-1.667 ( 1.5275 )
Squamous Cells Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	-1.800 ( 7.1554 )	0.000 ( 0.0000 )	1.000 ( 1.4142 )
Squamous Cells Week 8 (0, 2, 4, 2, 3)	999 ( 999 )	0.000 ( 0.0000 )	0.500 ( 1.0000 )	0.000 ( 0.0000 )	0.333 ( 0.5774 )
Squamous Cells Week 12 (1, 3, 5, 2, 3)	0.000 ( 999 )	-4.333 ( 7.5056 )	-2.200 ( 5.4955 )	0.000 ( 0.0000 )	0.333 ( 0.5774 )
Squamous Cells Week 16 (1, 5, 4, 5, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	-2.750 ( 5.5000 )	-0.200 ( 0.4472 )	0.000 ( 0.0000 )
Squamous Cells Week 20 (2, 4, 5, 6, 4)	1.000 ( 1.4142 )	-2.750 ( 5.5000 )	-1.400 ( 5.6391 )	-0.167 ( 0.9832 )	-0.750 ( 0.9574 )
Squamous Cells Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	1.000 ( 1.4142 )	1.000 ( 2.0000 )	-0.286 ( 0.4880 )	1.333 ( 4.1633 )
Squamous Cells Week 28 (1, 4, 5, 4, 3)	0.000 ( 999 )	-3.000 ( 6.0000 )	0.600 ( 1.3416 )	-0.250 ( 0.5000 )	-1.667 ( 1.5275 )
Squamous Cells Week 32 (2, 2, 4, 6, 2)	0.500 ( 0.7071 )	0.000 ( 0.0000 )	0.500 ( 1.0000 )	-0.667 ( 0.8165 )	-0.500 ( 0.7071 )
Squamous Cells Week 36 (1, 5, 4, 1, 1)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 999 )	0.000 ( 999 )
Squamous Cells Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	-2.750 ( 5.5000 )	0.750 ( 1.5000 )	0.000 ( 0.0000 )	-0.500 ( 0.7071 )
Squamous Cells Week 44 (1, 5, 5, 4, 2)	0.000 ( 999 )	-1.000 ( 2.2361 )	0.600 ( 1.3416 )	-0.250 ( 0.5000 )	-0.500 ( 0.7071 )
Squamous Cells Week 48 (2, 6, 4, 3, 3)	0.000 ( 0.0000 )	0.667 ( 1.6330 )	1.250 ( 1.8930 )	0.333 ( 0.5774 )	-1.000 ( 1.0000 )
Transitional Cells Week 1 (1, 4, 3, 5, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 2 (1, 4, 4, 4, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 8 (0, 3, 4, 2, 3)	999 ( 999 )	1.000 ( 1.7321 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 12 (1, 3, 5, 2, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.200 ( 0.4472 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 16 (1, 5, 4, 5, 2)	0.000 ( 999 )	0.400 ( 0.8944 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 20 (2, 4, 5, 6, 4)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 28 (1, 4, 5, 4, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 32 (2, 3, 4, 6, 3)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 36 (1, 6, 4, 1, 1)	0.000 ( 999 )	0.167 ( 0.4082 )	0.000 ( 0.0000 )	0.000 ( 999 )	0.000 ( 999 )
Transitional Cells Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	0.250 ( 0.5000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 44 (1, 5, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Transitional Cells Week 48 (2, 6, 4, 3, 4)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )

No statistical analyses for this end point

Secondary: Changes from Baseline in urinalysis parameters during the study (hyaline casts)

Top of page

End point title

Changes from Baseline in urinalysis parameters during the study (hyaline casts)

End point description

Hyaline casts was measured in cells per low power field (cells/LPF). The SS consisted of all randomized study participants who received at least 1 dose of IMP. Number of participants reflect those with non-missing urinalysis results during the study. Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed and for groups that had 0 participants analyzed. Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg).

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	1	4	3	5	3
Units: cells/LPF
arithmetic mean (standard deviation)
Week 1 (1, 4, 3, 5, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	1.000 ( 1.7321 )	-0.200 ( 0.4472 )	0.000 ( 0.0000 )
Week 2 (1, 4, 4, 4, 3)	0.000 ( 999 )	0.250 ( 0.5000 )	1.000 ( 1.1547 )	-0.250 ( 0.5000 )	0.333 ( 0.5774 )
Week 4 (1, 3, 5, 4, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	-0.800 ( 1.0954 )	-0.250 ( 0.5000 )	0.000 ( 0.0000 )
Week 8 (0, 3, 4, 2, 3)	999 ( 999 )	0.333 ( 0.5774 )	0.250 ( 0.5000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Week 12 (1, 3, 5, 2, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	5.000 ( 11.1803 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Week 16 (1, 5, 4, 5, 2)	0.000 ( 999 )	0.000 ( 0.0000 )	0.500 ( 1.0000 )	0.000 ( 0.0000 )	0.500 ( 0.7071 )
Week 20 (2, 4, 5, 6, 4)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	-0.600 ( 0.8944 )	1.500 ( 3.6742 )	-0.750 ( 1.5000 )
Week 24 (0, 4, 4, 7, 3)	999 ( 999 )	0.000 ( 0.0000 )	-0.250 ( 0.5000 )	0.857 ( 2.2678 )	0.333 ( 0.5774 )
Week 28 (1, 4, 5, 4, 3)	0.000 ( 999 )	0.000 ( 0.0000 )	-0.400 ( 0.8944 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Week 32 (2, 3, 4, 6, 3)	0.000 ( 0.0000 )	0.000 ( 0.0000 )	1.250 ( 2.5000 )	0.000 ( 0.0000 )	13.333 ( 23.0940 )
Week 36 (1, 6, 4, 1, 1)	0.000 ( 999 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	0.000 ( 999 )	0.000 ( 999 )
Week 40 (0, 4, 4, 4, 2)	999 ( 999 )	0.000 ( 0.0000 )	-0.500 ( 1.0000 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Week 44 (1, 5, 5, 4, 2)	0.000 ( 999 )	0.400 ( 0.8944 )	-0.400 ( 0.8944 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )
Week 48 (2, 6, 4, 3, 4)	0.000 ( 0.0000 )	1.167 ( 2.8577 )	0.000 ( 0.0000 )	0.000 ( 0.0000 )	-0.250 ( 0.5000 )

No statistical analyses for this end point

Secondary: Changes from Baseline in urinalysis parameters during the study (pH)

Top of page

End point title

Changes from Baseline in urinalysis parameters during the study (pH)

End point description

Urine pH was measured on a pH scale. The SS consisted of all randomized study participants who received at least 1 dose of IMP. Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 16 mg, BKZ 160 mg, BKZ 160 mg LD, BKZ 320 mg)

End point type

Secondary

End point timeframe

Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

End point values	Placebo (SS)	BKZ 16 mg (SS)	BKZ 160 mg (SS)	BKZ 160 mg LD (SS)	BKZ 320 mg (SS)
Number of subjects analysed	40	38	43	41	40
Units: pH
arithmetic mean (standard deviation)
Week 1 (40, 38, 43, 41, 40)	-0.138 ( 0.9198 )	0.197 ( 0.5875 )	0.023 ( 0.8014 )	0.085 ( 0.6011 )	0.000 ( 0.8321 )
Week 2 (42, 39, 43, 41, 41)	-0.155 ( 0.9072 )	0.154 ( 0.7708 )	-0.081 ( 0.7149 )	0.134 ( 0.8293 )	-0.012 ( 0.7541 )
Week 4 (41, 38, 41, 40, 41)	-0.195 ( 0.9211 )	0.026 ( 0.6571 )	-0.134 ( 0.8368 )	0.063 ( 0.6620 )	-0.098 ( 0.6729 )
Week 8 (41, 39, 42, 38, 41)	0.000 ( 0.7826 )	0.077 ( 0.7393 )	-0.024 ( 0.8762 )	0.263 ( 0.7235 )	0.024 ( 0.7579 )
Week 12 (40, 38, 43, 38, 41)	-0.100 ( 1.0203 )	0.237 ( 0.7600 )	-0.047 ( 0.6971 )	0.211 ( 0.6641 )	0.073 ( 0.8843 )
Week 16 (42, 38, 41, 38, 40)	-0.107 ( 0.8449 )	0.092 ( 0.7957 )	-0.122 ( 0.8199 )	0.118 ( 0.7207 )	0.088 ( 0.7240 )
Week 20 (40, 39, 42, 37, 40)	-0.113 ( 0.7884 )	0.269 ( 0.8649 )	-0.012 ( 0.8300 )	-0.054 ( 0.6539 )	0.063 ( 0.8929 )
Week 24 (39, 38, 41, 35, 39)	-0.154 ( 0.9400 )	-0.013 ( 0.8011 )	-0.085 ( 0.6605 )	0.100 ( 0.4820 )	-0.026 ( 0.6973 )
Week 28 (39, 38, 41, 35, 40)	-0.090 ( 0.8419 )	-0.053 ( 0.6657 )	-0.122 ( 0.7313 )	0.086 ( 0.6122 )	-0.088 ( 0.6783 )
Week 32 (39, 38, 40, 34, 39)	-0.218 ( 0.8335 )	-0.079 ( 0.7491 )	0.063 ( 0.8784 )	-0.103 ( 0.6717 )	-0.269 ( 0.5718 )
Week 36 (38, 38, 41, 34, 39)	-0.211 ( 0.8353 )	0.118 ( 0.7300 )	-0.195 ( 0.8506 )	-0.118 ( 0.6038 )	-0.077 ( 0.7569 )
Week 40 (37, 37, 40, 34, 39)	-0.216 ( 0.9394 )	-0.041 ( 0.6388 )	-0.188 ( 0.8525 )	-0.191 ( 0.5643 )	-0.154 ( 0.7448 )
Week 44 (36, 38, 41, 33, 38)	-0.458 ( 0.7780 )	-0.171 ( 0.7002 )	-0.159 ( 0.9044 )	-0.167 ( 0.6693 )	-0.171 ( 0.7285 )
Week 48 (38, 36, 40, 33, 40)	-0.092 ( 1.0771 )	-0.014 ( 0.7318 )	-0.200 ( 0.8533 )	-0.015 ( 0.7855 )	-0.100 ( 0.7528 )

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68)

Adverse event reporting additional description

At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.

Assessment type

Non-systematic

Dictionary name

MedDRA

Dictionary version

19.0

Reporting group title

Placebo (SS) - up to Wk 12

Reporting group description

This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).

Reporting group title

BKZ 320 mg (SS) - up to Wk 68

Reporting group description

This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.

Reporting group title

BKZ 160 mg & 160 mg LD (SS) - up to Wk 68

Reporting group description

Reporting group title

BKZ 16 mg (SS) - up to Wk 12

Reporting group description

This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.

Serious adverse events	Placebo (SS) - up to Wk 12	BKZ 320 mg (SS) - up to Wk 68	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 16 mg (SS) - up to Wk 12
Total subjects affected by serious adverse events
subjects affected / exposed	1 / 42 (2.38%)	0 / 80 (0.00%)	8 / 126 (6.35%)	0 / 39 (0.00%)
number of deaths (all causes)	0	0	0	0
number of deaths resulting from adverse events	0	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Cardiac disorders
Atrial fibrillation
subjects affected / exposed	1 / 42 (2.38%)	0 / 80 (0.00%)	0 / 126 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Nervous system disorders
Carpal tunnel syndrome
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders
Drug-induced liver injury
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Endocrine disorders
Goitre
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders
Osteoarthritis
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Infections and infestations
Cellulitis
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Otitis media chronic
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0
Hepatitis E
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5%

Non-serious adverse events	Placebo (SS) - up to Wk 12	BKZ 320 mg (SS) - up to Wk 68	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68	BKZ 16 mg (SS) - up to Wk 12
Total subjects affected by non serious adverse events
subjects affected / exposed	8 / 42 (19.05%)	29 / 80 (36.25%)	40 / 126 (31.75%)	9 / 39 (23.08%)
Vascular disorders
Hypertension
subjects affected / exposed	4 / 42 (9.52%)	2 / 80 (2.50%)	0 / 126 (0.00%)	0 / 39 (0.00%)
occurrences all number	4	2	0	0
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
subjects affected / exposed	0 / 42 (0.00%)	1 / 80 (1.25%)	0 / 126 (0.00%)	2 / 39 (5.13%)
occurrences all number	0	1	0	2
Psychiatric disorders
Insomnia
subjects affected / exposed	0 / 42 (0.00%)	3 / 80 (3.75%)	0 / 126 (0.00%)	2 / 39 (5.13%)
occurrences all number	0	4	0	2
Musculoskeletal and connective tissue disorders
Psoriatic arthropathy
subjects affected / exposed	3 / 42 (7.14%)	1 / 80 (1.25%)	2 / 126 (1.59%)	2 / 39 (5.13%)
occurrences all number	4	1	2	2
Infections and infestations
Ear infection
subjects affected / exposed	0 / 42 (0.00%)	0 / 80 (0.00%)	1 / 126 (0.79%)	2 / 39 (5.13%)
occurrences all number	0	0	1	2
Respiratory tract infection
subjects affected / exposed	0 / 42 (0.00%)	2 / 80 (2.50%)	8 / 126 (6.35%)	2 / 39 (5.13%)
occurrences all number	0	3	8	2
Bronchitis
subjects affected / exposed	1 / 42 (2.38%)	3 / 80 (3.75%)	7 / 126 (5.56%)	0 / 39 (0.00%)
occurrences all number	1	3	8	0
Nasopharyngitis
subjects affected / exposed	0 / 42 (0.00%)	11 / 80 (13.75%)	12 / 126 (9.52%)	3 / 39 (7.69%)
occurrences all number	0	11	15	3
Pharyngitis
subjects affected / exposed	0 / 42 (0.00%)	7 / 80 (8.75%)	4 / 126 (3.17%)	0 / 39 (0.00%)
occurrences all number	0	7	4	0
Upper respiratory tract infection
subjects affected / exposed	0 / 42 (0.00%)	8 / 80 (10.00%)	12 / 126 (9.52%)	1 / 39 (2.56%)
occurrences all number	0	10	12	1

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

09 Mar 2018

Protocol Amendment 2 was a substantial amendment dated 09 Mar 2018. The purpose of this protocol amendment was the following: •To update the study contact details for the sponsor study physician and clinical trial biostatistician. •To revise the withdrawal criteria Section to provide instructions for the management of study participants with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares during the study. •To amend the time window between doses during the Double-blind Period of the study. •To add new details for the IMP packaging. •To revise and clarify the SAE criteria for pregnancy for consistency. •To amend the table for identification/exclusion of alternative etiology to include aspartate aminotransferase (AST) and alanine aminotransferase (ALT). A total of 308 study participants were screened and 206 study participants were randomized at the time of this amendment.

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Biomarker assays were not rigorously validated, thus it was not possible to use results for PD as a secondary objective. The results were interpreted with caution for exploratory purpose, and thus are not shared in this report.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Clinical Trial Results: A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12

Primary: ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12

Secondary: ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12

Secondary: ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12

Secondary: ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12

Secondary: ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12

Secondary: PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Secondary: PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Secondary: PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Secondary: PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1

Secondary: Percentage of participants with at least one adverse event (AE) during the study

Secondary: Percentage of participants with at least one adverse event (AE) during the study

Secondary: Percentage of participants with at least one serious adverse event (SAE) during the study

Secondary: Percentage of participants with at least one serious adverse event (SAE) during the study

Secondary: Percentage of participants who withdrew due to an adverse event (AE) during the study

Secondary: Percentage of participants who withdrew due to an adverse event (AE) during the study

Secondary: Changes from Baseline in vital signs during the study (diastolic blood pressure, systolic blood pressure)

Secondary: Changes from Baseline in vital signs during the study (diastolic blood pressure, systolic blood pressure)

Secondary: Changes from Baseline in vital signs during the study (pulse rate)

Secondary: Changes from Baseline in vital signs during the study (pulse rate)

Secondary: Changes from Baseline in body weight during the study

Secondary: Changes from Baseline in body weight during the study

Secondary: Changes from Baseline in electrocardiogram (ECG) intervals during the study (QTcB, QTcF, PR, QRS, QT, RR)

Secondary: Changes from Baseline in electrocardiogram (ECG) intervals during the study (QTcB, QTcF, PR, QRS, QT, RR)

Secondary: Changes from Baseline in hematology parameters during the study (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

Secondary: Changes from Baseline in hematology parameters during the study (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB))

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular hemoglobin (HGB))

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular volume)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes mean corpuscular volume)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes)

Secondary: Changes from Baseline in hematology parameters during the study (erythrocytes)

Secondary: Changes from Baseline in hematology parameters during the study (hematocrit)

Secondary: Changes from Baseline in hematology parameters during the study (hematocrit)

Secondary: Changes from Baseline in hematology parameters during the study (platelets)

Secondary: Changes from Baseline in hematology parameters during the study (platelets)

Secondary: Changes from Baseline in biochemistry parameters during the study (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase)

Secondary: Changes from Baseline in biochemistry parameters during the study (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase)

Secondary: Changes from Baseline in biochemistry parameters during the study (albumin)

Secondary: Changes from Baseline in biochemistry parameters during the study (albumin)

Secondary: Changes from Baseline in biochemistry parameters during the study (bilirubin, creatinine, urate)

Secondary: Changes from Baseline in biochemistry parameters during the study (bilirubin, creatinine, urate)

Secondary: Changes from Baseline in biochemistry parameters during the study (calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium)

Secondary: Changes from Baseline in biochemistry parameters during the study (calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium)

Secondary: Changes from Baseline in biochemistry parameters during the study (urea nitrogen)

Secondary: Changes from Baseline in biochemistry parameters during the study (urea nitrogen)

Secondary: Changes from Baseline in urinalysis parameters during the study (erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells)

Secondary: Changes from Baseline in urinalysis parameters during the study (erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells)

Secondary: Changes from Baseline in urinalysis parameters during the study (hyaline casts)

Secondary: Changes from Baseline in urinalysis parameters during the study (hyaline casts)

Secondary: Changes from Baseline in urinalysis parameters during the study (pH)

Secondary: Changes from Baseline in urinalysis parameters during the study (pH)

Adverse events

Adverse events

More information

Substantial protocol amendments (globally)

Interruptions (globally)

Limitations and caveats

More information

Clinical Trial Results:
A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS